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ABSTRACT: 40 
 41 
The synthesis via phosphine-boranes of 13 new optically pure P-stereogenic diarylphosphines 42 
P(Het)PhR (Het = 4-dibenzofuranyl (DBF), 4-dibenzothiophenyl (DBT), 4-dibenzothiophenyl-S,S-43 
dioxide (DBTO2) and 1-thianthrenyl (TA); R = OMe, Me, i-Pr, Fc (ferrocenyl)) following the Jugé–44 
Stephan method is described. The ligands were designed with the aim of having a heteroatom in a 45 
position capable of interacting with a metal upon coordination. The ligands and their precursors have 46 
been fully characterised, including the determination of two crystal structures of phosphine-boranes. Ru 47 
neutral complexes of the type [RuCl2(η6-arene)(κP-P)] (arene = p-cymene and methyl benzoate) have 48 
been prepared and characterised, including three crystal structure determinations. Treatment of solutions 49 
of the complexes with TlPF6 allowed the preparation of well-defined cationic complexes [RuCl(η6-50 
arene)(κ2P,S-P)]PF6 for DBTand TA-based phosphines. The complexes possess a stereogenic Ru atom 51 
and in most of the cases they are present as a single isomer in solution. All the Ru complexes have been 52 
used in the asymmetric transfer hydrogenation of acetophenone in refluxing 2-propanol, with good 53 
activities and up to 70% ee. 54 
 55 
 56 
57 
INTRODUCITON 58 
 59 
The preparation of optically pure P-stereogenic compounds is still a considerable challenge despite their 60 
long history, stretching for more than a century,1,2 and their importance as ligands for transition metal-61 
based homogeneous catalysis.3–5 The lack of generality of most of the known synthetic methods and 62 
the long and tedious steps required to prepare such compounds can be blamed for the sluggish 63 
development of this area. This makes that even today the preparation of new ligands of this kind can be 64 
considered a valuable achievement. During the last twenty years, however, several very promising 65 
advances have been made,4 which have allowed the synthesis of new families of ligands with superior 66 
performance in Rhcatalysed hydrogenation and other reactions, and the pace of these advances has been 67 
increasing lately.6–17 At present, most of the ligands of this kind are prepared using 68 
phosphineboranes18–20 as intermediates and by asymmetric synthesis methods relying on chiral 69 
auxiliaries. Two of the most important routes are that developed by Jugé, Stephan and coworkers21,22 70 
furnishing diarylphosphines and that firstly devised by Evans and coworkers23 and much expanded by 71 
Imamoto and coworkers24,25 to give trialkylphosphines. Both methods are based on phosphine-boranes 72 
and employ organolithium reagents as nucleophiles or bases in at least one step. 73 
Joining these efforts, we have described several kinds of P-stereogenic monophosphines, initially 74 
prepared by resolution of the racemic ligands26–28 and more recently by the Jugé–Stephan29–35 or 75 
Evans32,36,37 method. They were initially employed in Pd-catalysed hydrovinylation29,32,34 and later 76 
in allylic substitution reactions31,34 and Ru-catalysed cyclopropanation33 and transfer 77 
hydrogenation33–35,37 reactions. 78 
We reasoned that it would be interesting to design families of new P-stereogenic monophosphines 79 
containing heteroatoms adequately located in the ligand in order to interact with the metal with a 80 
coordination bond or by a weaker secondary (hemilabile) interaction and study their performance in 81 
catalysis. With these ideas in mind, a recent paper by Hayes and coworkers38 describing the synthesis 82 
of P-stereogenic monophosphinimine ligands for Zn-catalysed ring-opening polymerisation of lactide 83 
caught our attention. In this paper the synthesis of P(4-dibenzofuranyl) MePh was described, albeit in 84 
the racemic form. This phosphine was prepared using 4-lithiodibenzofuran,39 easily prepared by direct 85 
o-lithiation of dibenzofuran (Scheme 1). 86 
This ligand has the heteroatom at the γ position with respect to the P atom, a feature that would create a 87 
favoured 5-membered ring upon interaction with a transition metal. Therefore, we started a study aiming 88 
to prepare P-stereogenic phosphines bearing a heterocyclic substituent with the following requirements: 89 
(i) the ligands should have the heteroatom of the heterocycle at the γ or δ position relative to the 90 
phosphorus atom, (ii) the heterocycle should be selectively lithiated at the β position, so it can be 91 
installed at the P atom by the Jugé–Stephan method and (iii) the heterocycle should be commercially 92 
available. After analysis of the literature, we concluded that dibenzofuran (DBF), dibenzothiophene 93 
(DBT) and thianthrene (TA) met these requirements (Scheme 2). 94 
The number of monophosphorus ligands or precursors bearing any of these substituents is very limited. 95 
With DBF, Haenel and coworkers39 first reported the preparation of 4-diphenylphosphinodibenzofuran 96 
in the course of their studies on lithiation of DBF and DBT. Much more recently several 4-97 
diphenylphosphinodibenzofuran oxides, substituted with different moieties at the dibenzofuran 98 
fragment, have been reported because they have interesting photochemical applications.40–43 Wills and 99 
coworkers44,45 prepared 4-bis(dimethylamino) phosphinodibenzofuran and condensed it at high 100 
temperature with a chiral diamine to obtain an optically pure diazaphospholidine, a ligand that was used 101 
in Pd-catalysed allylic substitution reactions. This is the only reported example of an optically pure 102 
monophosphorus ligand based on the DBF skeleton. Finally, Hayes and coworkers38 recently reported 103 
the synthesis of racemic (4-dibenzofuranyl)methylphenylphosphine as mentioned before, by 104 
deprotection of its phosphine-borane, previously obtained by reaction of methyllithium with (4-105 
dibenzofuranyl)methylphenylphosphineborane. With DBT, Rauchfuss, Rheingold and coworkers46 106 
reported the synthesis of 4-diphenylphosphino- and 4-di(p-tolyl)phosphinodibenzothiophene and some 107 
derived Ru complexes. The crystal structures of the former phosphine and a derived Fe complex were 108 
also described a few years later.47 4-Diphenylphosphinodibenzothiophene was also reported by Haenel 109 
and coworkers soon afterwards.39 The only optically pure monophosphorus ligand precursor with the 110 
DBT moiety was reported by Fiaud and coworkers,48 who attached an enantiomerically pure 2,5-111 
diphenylphospholane oxide moiety to the 4 position of DBT by Pd-catalysed C–P bond formation. 112 
Finally, no phosphines with the TA substituents have been described to the best of our knowledge. In 113 
addition, there are no examples of optically pure P-stereogenic phosphines bearing any of those 114 
heterocyclic substituents. 115 
In this paper we describe the synthesis of a series of new P-stereogenic phosphine-boranes containing a 116 
DBF, DBT or TA substituent employing the Jugé–Stephan method, the preparation of several types of 117 
complexes containing [Ru(η6-arene)] moieties and their application as precatalysts in the asymmetric 118 
transfer hydrogenation of acetophenone. 119 
 120 
 121 
 122 
 123 
 124 
125 
RESULTS AND DISCUSSION 126 
 127 
Ligand synthesis 128 
The desired ligands were designed to be obtainable by the Jugé–Stephan method,21,22 in which the 129 
groups are sequentially introduced at the phosphorus atom via organolithium reagents. Therefore, 130 
following slightly modified literature procedures, the selective monometallation of DBF,38 DBT49 and 131 
TA50 was successfully accomplished by ortholithiation with n-butyllithium under different conditions 132 
(Scheme 3). 133 
The solutions of the organolithiums were reacted with Jugé–Stephan’s oxazaphospholidine-borane 1 at 134 
low temperature giving aminophosphine-boranes 2-Het in good yields as white solids (Scheme 4). 135 
The acidic methanolysis of 2-Het proceeded smoothly, affording phosphinite-boranes 3-Het as pure 136 
pasty solids or oils after column chromatography purification. Treatment of these compounds with an 137 
excess of RLi (R = Me, i-Pr, t-Bu and Fc) at low temperatures was carried out to obtain a series of 138 
phosphine-boranes as resins or oils. It is known that this step is very sensitive to the bulkiness of the 139 
incoming organolithium reagent.29,51 Therefore, it is not surprising that in the case of methyllithium 140 
the reactions were successful for all the substrates, giving the methylphosphine-boranes 4-Het-Me in 141 
good yields. Isopropyllithium reacted well with 3-DBF and 3-DBT giving the desired 4-Het-iPr 142 
phosphine-boranes but reaction with 3-TA at −30 °C produced a compound containing two isopropyl 143 
groups. According to 1H and 13C NMR spectroscopy, one of them was bound to the P atom whereas the 144 
other was not. No further aliphatic hydrogen or carbon atoms could be detected. Addition of less than 145 
one equivalent of isopropyllithium led to the same product with two isopropyl groups along with 146 
incomplete conversion of the starting phosphinite-borane 3-TA. This fact indicates that isopropyllithium 147 
is not able to directly attack the phosphorus atom, so it probably reacts first with the thianthrene ring and 148 
opens it, releasing steric encumbrance at the P atom and allowing a rapid attack of a second equivalent 149 
of isopropyllithium. Although NMR suggested that only a single diastereomerically pure product was 150 
formed, we have been unable to clarify either its identity or its optical purity. Interestingly, the addition 151 
of isopropyllithium to a diethyl ether solution of thianthrene at −30 °C did not lead to any opened 152 
product but to the full recovery of unchanged thianthrene. Reaction of 3-Het with monolithiated 153 
ferrocene worked well for Het = DBF and DBT but not for TA, since unchanged 3-TA was isolated after 154 
workup. 155 
The introduction of the t-Bu group is (usually)51,52 impossible using the Jugé–Stephan method due to 156 
steric reasons.29 In line with this finding, reaction of 3-DBT and 3-TA with t-BuLi was unsuccessful 157 
since complex mixtures of products were obtained according to 31P NMR spectroscopy. In contrast, 158 
under carefully controlled conditions, 3-DBF reacted with t-BuLi to afford the phosphine 4-DBF-tBu, 159 
which could be isolated as an oil in 60% yield. It is possible that the hard oxygen atom of DBF assists 160 
the nucleophilic attack of t-BuLi by coordination of the Li cation.52 To take advantage of this reactivity, 161 
the triarylphosphine-borane 4-DBF-DBT was successfully prepared by reaction of 3-DBF with DBTLi. 162 
A peculiarity of this phosphine is that it suffers partial spontaneous deboronation and therefore the 163 
work-up had to be carried out under a nitrogen atmosphere to minimise the oxidation of the free 164 
phosphine. Due to this fact, the phosphine-borane was not isolated but fully deprotected with 165 
morpholine (see later) to yield the completely free phosphine, which was subsequently coordinated to 166 
ruthenium. 167 
All the intermediates have been fully characterised by the usual techniques and the details can be found 168 
in the Experimental section. Phosphine-boranes 4-DBF-Fc and 4-DBT-Fc were also characterised in the 169 
solid state by determination of their X-ray crystal structures (Fig. 1). 170 
The crystals contain discrete molecules having the expected S absolute configuration at the P atom. The 171 
distances and angles are in the range expected for similar compounds29,35,53 and are very similar for 172 
both structures. The only noticeable differences between the two structures are in the parameters around 173 
the heteroatom: for DBF, the two O–C distances are much shorter compared to the two S–C distances in 174 
DBT and the angle C–O–C is much wider than the angle C–S–C in DBT. In both structures, the 175 
heterocyclic substituent is essentially planar and the two Cp rings of the ferrocene are almost eclipsed, 176 
as observed in other ferrocenylphosphineboranes. 32,54,55 177 
It is well known that the sulfur atoms of DBT and TA can be oxidised to sulfoxides (SO)50,56–60 or 178 
sulfones (SO2).56,57,60–68 For this reason it was considered worth exploring the oxidation of the 179 
ligands containing these heterocycles because the sulfoxy group of the new ligands could interact with 180 
the metal during catalysis. Phosphine-borane 4-DBT-Me was therefore treated with a variety of oxidants 181 
such as MCPBA,58 H2O2/ HAcO,60,64–67 and CrO3/H5IO6 (Scheme 5).63 182 
With the treatment with MCPBA and H2O2/HAcO it was found that partial deprotection and oxidation 183 
of the P atom of the phosphine as well as formation of byproducts had taken place according to 31P 184 
NMR spectroscopy. In contrast, with CrO3/H5IO6 in acetonitrile63 a single product corresponding to 185 
the complete deprotection and oxidation, namely the trioxide 4-DBTO3-Me, could be isolated. It seems 186 
therefore that the borane protecting group cannot withstand the strongly oxidant conditions of the 187 
reaction. It was then reasoned that if oxidation of DBT was not possible once installed at the P atom, 188 
maybe the DBTO2 fragment could be introduced in the first step of the Jugé–Stephan method. To this 189 
end, DBT was oxidised with hydrogen peroxide66,67 and lithiated with n-BuLi (Scheme 6). 190 
The lithiation of DBTO2 has not been reported. After a series of experiments it was found that the best 191 
conditions consisted of adding n-BuLi to a solution of DBTO2 precooled at −78 °C, removing the cold 192 
bath immediately and stirring the mixture for 3 h at room temperature. Even under these conditions, 193 
however, the lithiation was incomplete and not always reproducible. Despite the rather unsatisfactory 194 
lithiation, it allowed the introduction of the oxidised heterocycle at the P atom and following the 195 
standard method compounds 2-DBTO2 and 3-DBTO2 could be prepared. The latter compound was 196 
treated with an excess of MeLi under usual conditions but did not give the expected 4-DBTO2-Me but 197 
dimethylphenylphosphine- borane.69,70 It is possible that the strongly electron-withdrawing sulfone 198 
group weakens the P–C bond to such an extent that it can be cleaved by methyllithium even at low 199 
temperature.71 Therefore no other phosphines with DBTO2 were prepared. Finally, the obtained 200 
phosphine-boranes were deprotected with morpholine under standard conditions29,53 to give the free 201 
phosphinites and phosphines L1–13 (Scheme 7). 202 
The free phosphines were all air-sensitive, especially the t-Bu-containing ligand L7 and hence after 203 
deprotection the 13 ligands were immediately coordinated to Ru moieties.  204 
 205 
Ru complexes 206 
Neutral complexes. The ligands were used to obtain the ruthenium neutral complexes of the type 207 
[RuCl2(η6-arene)(P)], with the arene being p-cymene or methyl benzoate (Scheme 8).34,35 208 
The complexes were easily prepared by splitting the usually employed ruthenium p-cymene dimer (D1) 209 
and for some of the ligands the much lesser used35 ruthenium methyl benzoate dimer (D2), in 210 
dichloromethane at room temperature as previously reported for analogous compounds.35 The products 211 
were obtained as red or brown solids that were characterised by IR, chemical microanalysis or MS and 212 
by multinuclear NMR in solution. The data confirmed the identity of the proposed structures and the 213 
purity of the products. Hence, single 31P resonances were found for all the complexes and due to the 214 
chirality of the phosphorus ligand, all the H and C atoms were potentially different. Accordingly, apart 215 
from the peaks corresponding to the phosphorus ligand, 4 distinct H (4.0–6.5 ppm region) and 6 C (80–216 
110 ppm) peaks appeared, respectively, in the 1H and 13C{1H} NMR spectra of the p-cymene 217 
complexes whereas 5 H resonances could be found for the methyl benzoate complexes. As expected, the 218 
latter complexes also featured a singlet at approximately 3.9 ppm in the 1H NMR spectra, corresponding 219 
to the COOMe group. Unexpectedly, for most of the methyl benzoate complexes a pair of peaks around 220 
53 ppm and another pair around  167 ppm can be seen in the 13C{1H} NMR spectra, corresponding to 221 
the methylic and carbonylic carbon atoms of the COOMe group. The observation of the two peaks is 222 
probably due to the presence of the two rotamers represented in Scheme 9 in the solution. 223 
Finally, a sharp band in the IR spectra of methyl benzoate complexes close to 1728 cm−1 confirms the 224 
presence of the carbonyl of the ester group. The complex Ru7 could not be obtained satisfactorily since 225 
an extremely broad 31P{1H} NMR spectrum resulted and multiple peaks in the 1H NMR spectrum 226 
could be observed. This can be due to the bulkiness of L7 precluding efficient coordination to the Ru 227 
unit. 228 
Single crystals, suitable for X-ray crystallography, could be obtained for complexes Ru5, Ru6 and Ru10 229 
by slow diffusion of hexane into saturated solutions of the complexes in dichloromethane. The 230 
representation of their molecular structures is given in Fig. 2. 231 
All the complexes adopt the typical pseudotetrahedral, “three-legged piano stool” geometry, with the Ru 232 
atom located in the centre of a distorted octahedron. The structures allow the confirmation of the 233 
expected absolute configurations of the P atoms (S for the free ligands). The crystals of complex Ru5 234 
contain two molecules in the unit cell, whose main difference is that the p-cymene is rotated 180° 235 
around the Ru–arene central axis. The most relevant metric parameters of the structures are given in 236 
Table 1. 237 
As commonly found for this type of compound, the η6-coordinated p-cymene ring is located in such a 238 
way that the imaginary line defined by the two Cl atoms is approximately parallel to the line passing 239 
through the substituted C atoms of the p-cymene group. It can also be seen that the heterocyclic 240 
substituent is almost completely flat. In general, the distances and angles are in the range expected for 241 
previously reported similar compounds.33,34,37,72,73 242 
 243 
Cationic complexes 244 
Neutral p-cymene Ru complexes were treated with thallium hexafluorophosphate (or tetrafluoroborate in 245 
the case of Ru10) in order to abstract the chloride ligand and force the coordination of the heteroatom of 246 
the heterocycle to the metal (Scheme 10).74–76 247 
Treatment of dichloromethane solutions of complexes Ru1 (δP,Ru1 = +112.7 ppm) and Ru6 (δP,Ru6 = 248 
+21.5 ppm), bearing a phosphine with the DBF group, with TlPF6 caused a rapid precipitation of TlCl 249 
that was filtered, the solvent removed and the crude product analysed by NMR. In both experiments, a 250 
singlet at +113.8 and +24.0 ppm respectively in the 31P{1H} spectra of the isolated product was 251 
observed. Since the values are almost unchanged from Ru1 and Ru6, it can be concluded that the desired 252 
complex with a five-membered chelate ring with the κ2P,O-coordinated phosphine did not form because 253 
a large downfield shift would be expected.77 1H NMR spectra, however, revealed that the products 254 
were not the starting complexes and that they contained the p-cymene and the phosphine moieties in a 1 255 
: 1 ratio. They could correspond to dimeric species although their constitution was not further 256 
investigated. In the case of Ru4 (δP,Ru4 = 117.0 ppm), after treatment with TlPF6, 31P{1H} NMR 257 
showed that 30% of the starting material was still present but another species slightly shifted upfield (δP 258 
= 112.0 ppm) had also formed. This species could indeed correspond to the desired κ2P,O-chelate since 259 
it is known that the ring contribution to the 31P shift is small and negative in six-membered rings.77 260 
Despite this, given that only partial conversion could be achieved, its synthesis was not pursued further. 261 
In contrast to the unsuccessful coordination of the O atom, the coordination of the S atom of the 262 
dibenzothiophenyl and thianthryl groups could be achieved, yielding cationic complexes Ru2′, Ru3′ and 263 
Ru9′-13′. A strong deshielding of the 31P signals (Δδ(Ru′–Ru) = 20–43 ppm) occurred upon formation 264 
of the 5-membered ring via coordination of the S atom, as expected.77 Similarly, in the 1H NMR the 265 
peaks of the H atoms of the coordinated arene ring shifted downfield approximately 1 ppm and in the 266 
13C{1H} the six C resonances also shifted roughly 5 ppm downfield. These downfield shifts possibly 267 
reflect the decreased electron density of the η6-coordinated arene ring due to the presence of a positive 268 
charge compared to the neutral Ru complexes. The identity of the complexes was also verified by 269 
elemental analyses or high resolution mass spectrometry as detailed in the Experimental section. The 270 
complex Ru11*′, bearing the methyl benzoate as coordinated arene, was also obtained by treating Ru11* 271 
with thallium hexafluorophosphate. 272 
An interesting aspect of the cationic Ru complexes described here is the possible formation of two 273 
diastereomeric complexes due to the presence of a stereogenic Ru atom (Scheme 10). NMR analysis 274 
showed a single 31P signal and a unique set of C and H signals for complexes Ru2′, Ru3′, Ru11′ and 275 
Ru11*′, suggesting that they are present as an optically pure species. In contrast, the two isomers could 276 
be detected for the rest of the complexes, since two 31P peaks and two sets of C and H signals were 277 
found as detailed in the Experimental section. The ratio between isomers was approximately 1 : 4 for 278 
complexes Ru9′ and Ru10′ and 1 : 2 for Ru12′ and Ru13′. It seems that there is no simple correlation 279 
between the structure of the ligand and the isomeric ratio. Despite many attempts we were unable to 280 
obtain crystals suitable to perform X-ray diffraction studies of any of the complexes in order to ascertain 281 
the absolute configuration of the main isomer. 282 
 283 
Ru-catalysed transfer hydrogenation 284 
The reduction of ketones to alcohols is an extremely important transformation in organic chemistry that 285 
can be catalytically performed by hydrogenation using hydrogen gas, or in a safer way, by transfer 286 
hydrogenation, using a hydrogen donor.78,79 The latter reaction has been studied with a large number 287 
of soluble Ru(II) systems, very often chiral, to obtain enantioenriched alcohols.80–82 The model 288 
substrate for the asymmetric transfer hydrogenation is acetophenone and the typical conditions involve 289 
carrying out the reaction in refluxing 2-propanol in the presence of a base (Scheme 11). 290 
Although not the most typical precursors, Ru complexes of the type [RuCl2(η6-arene)(P)] are easy to 291 
prepare and they are active in the reaction, as shown by us33–35,37 and other groups.74,83–86 The 292 
enantioselectivities of our systems with P-stereogenic phosphines are, however, rather low (up to 50% 293 
ee),33,35,37 so the performance of neutral and cationic Ru complexes with the new heterocyclic 294 
phosphines was studied (Table 2). 295 
The precursors were activated for 15 min in the presence of t-BuOK before the addition of acetophenone 296 
to form the catalytically active ruthenium–hydride species.87 All were active in the reaction, resulting in 297 
full conversion at 24 h. At shorter reaction times, however, notable differences in activity can be seen 298 
depending on the structure of the precursor. In most of the cases, neutral κP-coordinated complexes lead 299 
to more active precursors compared to cationic κ2P,S-coordinated counterparts (cf. for example entries 300 
15 and 17 or 21 and 23). The complexes with methyl benzoate give more active systems than those with 301 
p-cymene (cf. for example entries 8 and 9 or 15 and 16), in line with previously published results for 302 
similar systems.35 These findings suggest that η6-arene decoordination or slippage (hapticity reduction) 303 
probably occurs during the catalytic cycle. Such a process is easier for electron poor methyl benzoate 304 
complexes compared to p-cymene analogues and also for neutral complexes compared to cationic 305 
counterparts. 306 
Finally, the enantioselection is very low for most of the precursors, as usually found with similar 307 
monophosphorus ligands.33,35 The precursors with L11 (entries 15–18) are moderately 308 
enantioselective, except Ru11′ (entry 17). Interestingly, the same value of 70% ee was obtained with 309 
complexes Ru11* and Ru11*′ (entries 16 and 18 respectively), pointing to the formation of a common 310 
intermediate under catalytic conditions. It is worth noting that Ru11 and Ru11* both form single 311 
cationic species in solution, a fact that could be beneficial for the enantioselectivity. 312 
313 
CONCLUSIONS 314 
 315 
In this paper the Jugé–Stephan method has allowed the preparation of 13 optically pure P-stereogenic 316 
diaryl monophosphinites and monophosphines of the type PPh(Het)R (Het = 4-DBF, 4-DBT, 1-TA and 317 
4-DBTO2; R = OMe, Me, i-Pr, t-Bu, Fc) by direct lithiation of the heterocycle. The ligands are a 318 
valuable addition to the small number of optically pure P-stereogenic ligands with a heterocyclic 319 
substituent. 320 
The ligands had been designed with the idea of introducing the heteroatom (A) at a position capable of 321 
interacting with the ruthenium centre via the formation of a favoured five-membered κ2P,A-chelate. 322 
This coordination has been achieved for DBT- and TA-containing phosphines but not for the DBFbased 323 
ligands. This is possibly due to the hard character of the oxygen atom, showing less tendency to 324 
coordinate to the Ru atom compared to sulfur. An important stereoselection in the formation of the 325 
stereogenic Ru atom has been observed for most of the ligands. 326 
The obtained complexes have been used in catalytic transfer hydrogenation of acetophenone with the 327 
aim of comparing the performance of the new ligands with previously reported systems based in P-328 
stereogenic PArPhR ligands (Ar = polycyclic aromatic group).33–35,37,87 It has been found that the 329 
activities are similar to some of the previous generation precursors but one of the ligands, L11, gives a 330 
considerably higher enantioselectivity. 331 
332 
EXPERIMENTAL SECTION 333 
 334 
General data 335 
All compounds were prepared under a purified nitrogen atmosphere using standard Schlenk and 336 
vacuum-line techniques. The solvents were purified using a solvent purification system or by standard 337 
procedures88 and kept under nitrogen. 1H, 13C{1H}, and 31P{1H} and HSQC 1H-13C NMR spectra 338 
were recorded using 300 and 400 MHz spectrometers using CDCl3 as a solvent unless otherwise 339 
specified. Chemical shifts are reported downfield from standards. The protons of BH3 of the phosphine-340 
boranes group appeared in the aliphatic region of the spectra as very broad bands and have not been 341 
assigned. IR spectra were recorded in KBr and the main absorption bands are expressed in cm−1. High-342 
resolution mass analyses (HRMS) were carried out on a time-of-flight instrument using electrospray 343 
ionisation. Optical rotations were measured at rt using a sodium lamp at the sodium D-line wavelength 344 
(589.592 nm). For all the determinations, the solvent was CH2Cl2 and the concentration was 1 g per 100 345 
mL. Transfer hydrogenation reactions were analysed by GC with He as a carrier gas. 346 
Oxazaphospholidine-borane 1 (prepared from (1R,2S)-(−)-ephedrine),21 dibenzothiophene 347 
dioxide,66,67 and Ru dimer D289 were prepared using literature procedures whereas other reagents 348 
were used as received from commercial suppliers. 349 
350 
SYNTHESIS OF THE LIGANDS 351 
 352 
2-DBF, (1R,2S)-2-{[(S)-(4-dibenzofuranyl)phenylphosphanyl] methylamino}-1-phenylpropan-1-ol-353 
borane. Dibenzofuran (1.85 g, 11.0 mmol) was dissolved in 30 mL of THF in a Schlenk flask. The 354 
solution was cooled to −78 °C and then 1.6 M n-BuLi solution in hexanes (6.9 mL, 11.0 mmol) was 355 
added using a syringe. The resulting brown solution was removed from the cold bath, left stirring for 30 356 
min at room temperature and then recooled to −78 °C. At the same time oxazaphospholidine-borane 1 357 
(2.85 g, 10.0 mmol) was dissolved in 40 mL of THF and the solution was cooled down to −78 °C. The 358 
content of the first flask was slowly transferred to the second Schlenk flask via cannula and the resulting 359 
mixture was stirred for 14 h. Around 30 mL of water were added to the orange solution and THF was 360 
evaporated. The dark-brown residue was extracted with dichloromethane (3 × 30 mL) and the combined 361 
organic phases were washed with water and dried with anhydrous sodium sulfate. The suspension was 362 
filtered and the solvents were evaporated to dryness, leaving a yellowish pasty solid that was purified by 363 
column chromatography (flash SiO2, from 95 : 5 to 80 : 20 of hexane/ethyl acetate). The title product 364 
was obtained as a whitish solid. Yield: 3.52 g (77%). 365 
1H NMR (300 MHz): 8.11 (dt, J = 7.8, 1.2, 1H), 7.96 (dm, J = 6.6, 1H), 7.78 (ddd, J = 12.3, 7.5, 1.2, 366 
1H), 7.58 (dm, J = 8.1, 1H), 7.51–7.18 (m, Ar, 13H), 4.90 (d, 3JHH = 6.0, 1H), 4.45 (m, 1H), 2.63 (d, 367 
3JHP = 8.1, 3H), 1.29 (d, 3JHH = 6.6, 3H). 13C{1H} NMR (101 MHz): 156.3–111.6 (C, CH, Ar), 78.6 368 
(d, 3JCP = 6.2, CH), 58.2 (d, 2JCP = 11.0, CH), 30.9 (d, 2JCP = 4.4, CH3), 13.0 (s, CH3). 31P{1H} 369 
NMR (121 MHz): +67.5 (br, s). HRMS: calcd for C28H27NO2P ([M] + H − BH3), 440.1779; found, 370 
440.1771. [α]D = +66.2°. 371 
2-DBT, (1R,2S)-2-{[(S)-(4-dibenzothiophenyl)phenylphosphanyl] methylamino}-1-phenylpropan-1-ol-372 
borane. Dibenzothiophene (2.03 g, 11.0 mmol) was dissolved in 30 mL of THF in a Schlenk flask. The 373 
solution was cooled to −78 °C and then 1.6 M n-BuLi solution in hexanes (6.9 mL, 11.0 mmol) was 374 
added using a syringe. The resulting brown solution was removed from the cold bath, left stirring at 0 °C 375 
for 5 h and recooled to −78 °C. At the same time oxazaphospholidineborane 1 (2.85 g, 10.0 mmol) was 376 
dissolved in 40 mL of THF and the solution was cooled down to −78 °C. The content of the first flask 377 
was slowly transferred to the second Schlenk flask via cannula and the resulting mixture was stirred for 378 
14 h. Around 30 mL of water were added to the brownyellow solution and THF was evaporated. The 379 
white residue was extracted with dichloromethane (3 × 30 mL) and the combined organic phases were 380 
washed with water and dried with anhydrous sodium sulfate. The suspension was filtered and the 381 
solvents were evaporated to dryness, leaving a white pasty solid, which was purified by column 382 
chromatography (flash SiO2, from 95 : 5 to 80 : 20 of hexane/ethyl acetate). The title product was 383 
obtained as a white solid. Yield: 4.11 g (87%). 384 
1H NMR (400 MHz): 8.29 (m, 1H), 8.18 (m, 1H), 7.84 (m, 1H), 7.73 (m, 1H), 7.58–7.42 (m, Ar, 9H), 385 
7.34 (t, J = 7.6, 2H), 7.27 (t, J = 6.4, 1H), 4.96 (s, br, 1H), 4.47 (m, 1H), 2.75 (d, 3JHP = 7.6, 3H), 1.36 386 
(d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 142.4–121.4 (C, CH, Ar), 78.9 (d, 3JCP = 2.7, CH), 387 
58.5 (d, 2JCP = 10.4, CH), 31.6 (d, 2JCP = 4.3, CH3), 11.3 (d, 3JCP = 5.4, CH3). 31P{1H} NMR (121 388 
MHz): +70.1 (br, s). HRMS: calcd for C28H27NOPS ([M] + H − BH3), 456.1551; found, 456.1540. 389 
[α]D = +52.2°. 390 
2-TA, (1R,2S)-2-{[(S)-(1-thianthrenyl)phenylphosphanyl] methylamino}-1-phenylpropan-1-ol-borane. 391 
Thianthrene (600 mg, 2.8 mmol) was dissolved in 40 mL of THF in a Schlenk flask. The solution was 392 
cooled to −78 °C and then 1.6 M n-BuLi solution in hexanes (2.3 mL, 3.7 mmol) was added using a 393 
syringe. The resulting brown solution was allowed to reach room temperature and then was refluxed for 394 
1 h, cooled to room temperature and then to −78 °C. At the same time oxazaphospholidine-borane 1 395 
(720 mg, 2.5 mmol) was dissolved in 40 mL of THF and the solution was cooled down to −78 °C. The 396 
content of the first flask was slowly transferred to the second Schlenk flask via cannula and the resulting 397 
mixture was stirred for 14 h. Around 30 mL of water were added to the brown-yellow solution and THF 398 
was evaporated. The white residue was extracted with dichloromethane (3 × 30 mL) and the combined 399 
organic phases were washed with water and dried with anhydrous sodium sulfate. The suspension was 400 
filtered and the solvents were evaporated to dryness, leaving a white pasty solid, which was purified by 401 
column chromatography (flash SiO2, from 95 : 5 to 80 : 20 of hexane/ethyl acetate). The title product 402 
was obtained as a white solid. Yield: 1.15 g (91%). 403 
1H NMR (400 MHz): 7.67 (dt, J = 7.6, 1.2, 1H), 7.52–7.43 (m, Ar, 7H), 7.39–7.27 (m, Ar, 6H), 7.22 (td, 404 
J = 7.6, 1.6, 1H), 7.15 (td, J = 7.6, 1.6, 1H), 7.02 (dd, J = 7.6, 1.6, 1H), 4.98 (d, J = 4.4, 1H), 4.45 (m, 405 
1H), 2.63 (d, 3JHP = 7.2, 3H), 1.32 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 142.4–126.2 (C, 406 
CH, Ar), 79.0 (d, 3JCP = 2.8, CH), 58.4 (d, 2JCP = 10.7, CH), 31.4 (d, 2JCP = 4.1, CH3), 12.0 (d, 3JCP 407 
= 4.1, CH3). 31P{1H} NMR (162 MHz): +71.9 (br, s). HRMS: calcd for C28H27NOPS2 ([M] + H − 408 
BH3), 488.1272; found, 488.1267. [α]D = +40.4°. 409 
2-DBTO2, (1R,2S)-2-{[(S)-(4-dibenzothiophenyldioxide)phenylphosphanyl] methylamino}-1-410 
phenylpropan-1-ol-borane. Dibenzothiophene- S,S-dioxide (1.19 g, 5.5 mmol) was dissolved in 40 mL 411 
of THF in a Schlenk flask. The solution was cooled to −78 °C and then 1.6 M n-BuLi solution in 412 
hexanes (3.4 mL, 5.5 mmol) was added using a syringe. The resulting brown solution was removed from 413 
the cold bath, left stirring at room temperature for 3 h and recooled to −78 °C. At the same time 414 
oxazaphospholidine-borane 1 (1.43 g, 5.5 mmol) was dissolved in 35 mL of THF and the solution was 415 
cooled down to −78 °C. The content of the first flask was slowly transferred to the second Schlenk flask 416 
via cannula and the resulting mixture was stirred for 14 h. Around 30 mL of water were added to the 417 
brown-yellow solution and THF was evaporated. The white residue was extracted with dichloromethane 418 
(3 × 30 mL) and the combined organic phases were washed with water and dried with anhydrous sodium 419 
sulfate. The suspension was filtered and the solvents were evaporated to dryness, leaving a white solid. 420 
Yield: 1.25 g (45%). 421 
1H NMR (400 MHz): 7.97 (m, 2H), 7.91. (dt, J = 7.6, 1.2, 1H), 7.79 (d, J = 8.0, 1H), 7.75 (d, J = 7.6, 422 
1H), 7.62 (td, J = 7.6, 1.2, 1H), 7.57 (m, 1H), 7.55–7.50 (m, 4H), 7.45 (m, 1H), 7.39 (d, J = 7.6, 2H), 423 
7.29 (td, J = 7.6, 2.0, 2H), 7.20 (tt, J = 7.2, 1.2, 1H), 5.11 (d, J = 2.8, 1H), 4.30 (m, 1H), 2.84 (d, 3JHP = 424 
8.4, 3H), 1.24 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 142.4–121.2 (C, CH, Ar), 78.7 (d, 3JCP 425 
= 1.5, CH), 59.3 (d, 2JCP = 9.9, CH), 33.9 (d, 2JCP = 3.9, CH3), 9.6 (d, 3JCP = 7.2, CH3). 31P{1H} 426 
NMR (162 MHz): +73.4 (br, s). HRMS: calcd for C28H27NO3PS ([M] + H − BH3), 488.1449; found, 427 
488.1457. [α]D = +66.1°.  428 
3-DBF, (R)-(4-dibenzofuranyl)methoxyphenylphosphineborane. Aminophosphine-borane 2-DBF (3.52 429 
g, 7.7 mmol) was dissolved in 200 mL of freshly distilled methanol, concentrated H2SO4 (0.84 mL, 430 
1.51 g, 15.4 mmol) was carefully added and the solution was stirred for 14 h. The solvent was removed 431 
in vacuo and the crude was purified by column chromatography (flash SiO2, 95 : 5 hexane/ethyl 432 
acetate). The title product was obtained as a pale brown oil. Yield: 1.67 g (67%). 433 
1H NMR (400 MHz): 8.13 (dt, J = 7.6, 1.2, 1H), 7.98–7.91 (m, 4H), 7.58 (d, J = 12.0, 1H), 7.56 (d, J = 434 
12.0, 1H), 7.51–7.43 (m, 4H), 7.36 (m, 1H), 3.85 (d, 3JHP = 12.4, 3H). 13C{1H} NMR (101 MHz): 435 
156.1–111.6 (C, CH, Ar), 54.3 (d, 2JCP = 2.7, CH3). 31P{1H} NMR (121 MHz): +106.6 (d, br, J ≈ 88). 436 
HRMS: calcd for C19H22BNO2P ([M] + NH4), 338.1481; found, 338.1472. [α]D = –81.9°. 437 
3-DBT, (R)-(4-dibenzothiophenyl)methoxyphenylphosphineborane. The procedure was the same as that 438 
used to prepare 3-DBF but starting from precursor 2-DBT (2.06 g, 4.4 mmol). The desired phosphinite-439 
borane was obtained as a colourless oil. Yield: 1.19 g (81%). 440 
1H NMR (400 MHz): 8.32 (d, J = 8.0, 1H), 8.17 (m, 1H), 8.09 (dd, J = 13.2, 7.6, 1H), 7.82–7.76 (m, 441 
3H), 7.60 (td, J = 7.2, 2.0, 1H), 7.53–7.40 (m, 5H), 3.86 (d, 3JHP = 12.4, 3H). 13C{1H} NMR (101 442 
MHz): 141.1–121.5 (C, CH, Ar), 54.2 (d, 2JCP = 2.3, CH3). 31P{1H} NMR (121 MHz): +110.6 (d, br, 443 
J ≈ 89). HRMS: calcd for C19H22BNOPS ([M] + NH4), 354.1253; found, 354.1252. [α]D = –78.0°. 444 
3-TA, (R)-methoxyphenyl(1-thianthrenyl)phosphine-borane. The procedure was similar to that used to 445 
prepare 3-DBF but starting from precursor 2-TA (1.15 g, 2.3 mmol) and stirring for 3 days. The desired 446 
phosphinite-borane was obtained as a white pasty solid. Yield: 447 mg (53%). 447 
1H NMR (400 MHz): 7.91 (ddd, J = 11.2, 7.6, 1.2, 1H), 7.74–7.69 (m, 3H), 7.52 (td, J = 7.2, 1.2, 1H), 448 
7.46–7.37 (m, 4H), 7.21 (td, J = 7.6, 1.6, 1H), 7.12 (td, J = 7.6, 1.2, 1H), 6.96 (dd, J = 7.6, 1.2, 1H), 3.80 449 
(d, 3JHP = 12.4, 3H). 13C{1H} NMR (101 MHz): 140.0–127.0 (C, CH, Ar), 54.1 (d, 2JCP = 2.5, CH3). 450 
31P{1H} NMR (162 MHz): +109.3 (d, br, J ≈ 83). HRMS: calcd for C19H22BNOPS2 ([M] + NH4), 451 
386.0973; found, 386.0976. [α]D = –10.5°. 452 
3-DBTO2, (R)-(4-dibenzothiophenyl dioxide)methoxyphenylphosphine- borane. The procedure was the 453 
same as that used to prepare 3-DBF but starting from precursor 2-DBTO2 (1.00 g, 3.0 mmol). The 454 
desired phosphinite-borane was obtained as a white solid. Yield: 433 mg (59%). 455 
1H NMR (400 MHz): 7.93–7.78 (m, 6H), 7.68–7.62 (m, 2H), 7.56 (td, J = 7.6, 0.8, 1H), 7.52–7.42 (m, 456 
3H), 3.99 (d, 3JHP = 12.0, 3H). 13C{1H} NMR (101 MHz): 139.4–121.3 (C, CH, Ar), 55.4 (d, 2JCP = 457 
2.0, CH3). 31P{1H} NMR (162 MHz): +112.0 (d, br, J ≈ 73). HRMS: calcd for C19H22BNO3PS ([M] 458 
+ NH4), 386.1151; found, 386.1156. [α]D = –291.1°.  459 
4-DBF-Me, (S)-(4-dibenzofuranyl)methylphenylphosphineborane. Methoxyphosphine-borane 3-DBF 460 
(673 mg, 2.1 mmol) was dissolved in 30 mL diethyl ether, and the solution was cooled down to −30 °C. 461 
A 1.6 M MeLi solution in diethyl ether (2.6 mL, 4.2 mmol) was added using a syringe and the mixture 462 
was stirred for 1 h before slowly warming it to room temperature. About 15 mL of water were added 463 
and the mixture was extracted with diethyl ether (3 × 10 mL), the combined organic phases were washed 464 
with 20 mL of water and dried with anhydrous sodium sulfate. After filtration, the solvent was removed 465 
in vacuo and the crude product was purified by column chromatography (flash SiO2, 95 : 5 hexane/ethyl 466 
acetate). The title product was obtained as a colourless oil. Yield: 523 mg (82%). 467 
1H NMR (400 MHz): 8.11 (d, J = 7.6, 1H), 8.00–7.95 (m, 2H), 7.85–7.80 (m, 2H), 7.59–7.55 (m, 2H), 468 
7.52–7.33 (m, 5H), 2.23 (d, 2JHP = 10.8, 3H). 13C{1H} NMR (101 MHz): 156.9–111.6 (C, CH, Ar), 469 
11.1 (d, 1JCP = 41.6, CH3). 31P{1H} NMR (121 MHz): +7.7 (d, br, J ≈ 81). HRMS: calcd for 470 
C19H22BNOP ([M] + NH4), 322.1532; found, 322.1530. [α]D = +140.8°. 4-DBF-iPr, (S)-(4-471 
dibenzofuranyl)isopropylphenylphosphineborane. The procedure was the same as that used to prepare 472 
4-DBF-Me. Starting from 3-DBF (1.15 g, 3.6 mmol) and 0.7 M i-PrLi solution in pentane (15.2 mL, 473 
10.8 mmol) the desired phosphinite-borane was obtained as a colourless oil. Yield: 897 mg (75%). 474 
1H NMR (400 MHz): 8.15–7.97 (m, 5H), 7.66 (d, J = 8.0, 1H), 7.53 (td, J = 7.6, 1.2, 1H), 7.45–7.38 (m, 475 
5H), 3.67 (m, 1H), 1.29 (dd, 3JHP, 3JHH = 17.2, 7.2, 3H), 1.16 (dd, 3JHP, 3JHH = 17.2, 6.8, 3H). 476 
13C{1H} NMR (101 MHz): 156.7–111.7 (C, CH, Ar), 22.6 (d, 1JCP = 37.9, CH), 17.1 (d, 2JCP = 2.8, 477 
CH3), 16.8 (d, 2JCP = 2.9, CH3). 31P{1H} NMR (121 MHz): +26.1 (d, br, J ≈ 77). HRMS: calcd for 478 
C21H26BNOP ([M] + NH4), 350.1845; found, 350.1842. [α]D = +228.9°. 479 
4-DBF-tBu, (S)-(tert-butyl)(4-dibenzofuranyl)phenylphosphine- borane. The procedure was the same as 480 
that used to prepare 4-DBF-Me. Starting from 3-DBF (732 mg, 2.1 mmol) and 1.6 M t-BuLi solution 481 
(1.5 mL, 2.3 mmol) the desired phosphinite-borane was obtained as a colourless oil. Yield: 440 mg 482 
(60%). 483 
1H NMR (400 MHz): 8.17–8.12 (m, 2H), 7.98 (td, J = 7.6, 0.8, 1H), 7.90–7.85 (m, 2H), 7.49–7.43 (m, 484 
4H), 7.42–7.36 (m, 3H), 1.41 (d, 3JHP = 14.8, 9H). 13C{1H} NMR (101 MHz): 155.4–111.7 (C, CH, 485 
Ar), 31.8 (d, 1JCP = 31.3, C), 27.8 (d, 2JCP = 3.0, CH3). 31P{1H} NMR (121 MHz): +36.7 (d, br, J ≈ 486 
70). HRMS: calcd for C22H28BNOP ([M] + NH4), 364.2002; found, 350.2014. [α]D = +82.3°. 487 
4-DBF-Fc, (S)-(4-dibenzofuranyl)ferrocenylphenylphosphineborane. Ferrocene (2.5 g, 13.4 mmol) was 488 
dissolved in 20 Ml of THF in a Schlenk flask. The solution was cooled to 0 °C, 1.6 M t-BuLi solution in 489 
pentane (16.7 mL, 26.9 mmol) was added using a syringe and the mixture was left stirring for 2 h. At 490 
this point 40 mL of hexane were added and the solution was cooled down to −78 °C, which caused the 491 
precipitation of FcLi. The solid was filtered under nitrogen, washed with hexane and dried in vacuo. In 492 
parallel, 3-DBF (2.15 g, 6.7 mmol) was dissolved in 20 mL of THF and the solution was cooled down to 493 
−78 °C. Solid FcLi was rapidly added to that solution and the mixture was left stirring for 14 h. About 494 
15 mL of water were added and most of the THF was removed in vacuo. The mixture was extracted 495 
with dichloromethane (3 × 10 mL), the combined organic phases were washed with 20 mL of water and 496 
dried with anhydrous sodium sulfate. After filtration, the solvent was removed in vacuo and the red 497 
crude product was purified by column chromatography (flash SiO2, 70 : 30 hexane/dichloromethane) 498 
and recrystallized in dichloromethane/hexane. The title product was obtained as an orange solid. Yield: 499 
1.80 g (56%). 500 
1H NMR (400 MHz): 8.13 (d, J = 7.6, 1H), 8.04 (dd, J = 12.8, 7.6 1H), 7.96 (d, J = 6.8, 1H), 7.67–7.62 501 
(m, 2H), 7.48 (t, J = 7.6, 1H), 7.44–7.35 (m, 6H), 4.69 (s, br, 2H), 4.53 (s, br, 1H), 4.49 (s, br, 1H), 4.00 502 
(s, br, 5H). 13C{1H} NMR (101 MHz): 156.6–111.8 (C, CH, Ar), 74.1 (d, JCP = 13.5, CH), 73.0 (d, 503 
JCP = 7.8, CH), 71.9 (d, JCP = 7.7, CH), 71.6 (d, JCP = 8.5, CH), 69.7 (s, 5CH), 67.7 (d, JCP = 70.5, 504 
C). 31P{1H} NMR (162 MHz): +12.6 (d, br, J ≈ 43). HRMS: calcd for C28H21FeOP ([M] − BH3), 505 
460.0679; found, 460.0663. [α]D = +65.4°. 506 
4-DBT-Me, (S)-(4-dibenzothiophenyl)methylphenylphosphine-borane. The procedure was the same as 507 
that used to prepare 4-DBF-Me. Starting from 3-DBT (580 mg, 1.7 mmol) and 1.6 M MeLi solution (1.2 508 
mL, 1.7 mmol) the desired phosphine-borane was obtained as a colourless oil. Yield: 357 mg (70%). 509 
1H NMR (400 MHz): 8.31 (dt, J = 8.0, 1.2, 1H), 8.16 (m, 1H), 8.08 (ddd, J = 12.8, 7.2, 1.2, 1H), 7.74 510 
(m, 1H), 7.70–7.64 (m, 2H), 7.61 (td, J = 7.6, 1.6, 1H), 7.52–7.40 (m, 5H), 2.09 (d, 2JHP = 10.0, 3H). 511 
13C{1H} NMR (101 MHz): 142.2–121.5 (C, CH, Ar), 10.0 (d, 1JCP = 40.2, CH3). 31P{1H} NMR (121 512 
MHz): +13.2 (d, br, J ≈ 77). HRMS: calcd for C19H22BNPS ([M] + NH4), 338.1304; found, 338.1293. 513 
[α]D = +41.5°. 514 
4-DBT-iPr, (S)-(4-dibenzothiophenyl)isopropylphenylphosphine-borane. The procedure was the same as 515 
that used to prepare 4-DBF-iPr. Starting from 3-DBT (1.00 g, 3.0 mmol) and 0.7 M i-PrLi solution in 516 
pentane (6.4 mL, 4.5 mmol) the desired phosphine-borane was obtained as a colourless oil. Yield: 985 517 
mg (95%). 518 
1H NMR (400 MHz): 8.10 (dt, J = 8.0, 1.6, 1H), 8.02 (dd, J = 7.6, 1.2, 1H), 7.96 (m, 1H), 7.71–7.66 (m, 519 
2H), 7.58 (m, 1H), 7.41 (td, J = 7.6, 2.0, 1H), 7.34–7.24 (m, 3H), 7.11 (d, J = 7.2, 1H), 7.04 (d, br, J = 520 
8.4, 1H), 3.17 (m, 1H), 1.23 (dd, 3JHP, 3JHH = 16.0, 6.8, 3H), 1.01 (dd, 3JHP, 3JHH = 16.8, 6.8, 3H). 521 
13C{1H} NMR (101 MHz): 142.3–121.5 (C, CH, Ar), 21.3 (d, 1JCP = 36.0, CH), 17.3 (d, 2JCP = 1.6, 522 
CH3), 17.1 (d, 2JCP = 2.5, CH3). 31P{1H} NMR (121 MHz): +29.7 (d, br, J ≈ 50). HRMS: calcd for 523 
C21H26BNPS ([M] + NH4), 366.1617; found, 366.1622. [α]D = +40.4°. 524 
4-DBT-Fc, (S)-(4-dibenzothiophenyl)ferrocenylphenylphosphine-borane. The procedure was the same 525 
as that used to prepare 4-DBT-Fc. Starting from ferrocene (1.31 g, 7.0 mmol) and 3-DBT (1.18 g, 3.5 526 
mmol) the desired phosphine-borane was obtained as an orange solid. Yield: 1.36 g (79%). 527 
1H NMR (400 MHz): 8.26 (d, J = 7.6, 1H), 8.14 (dd, J = 6.4, 2.4, 1H), 7.76–7.67 (m, 4H), 7.56–7.39 (m, 528 
6H), 4.75 (s, br, 1H), 4.56 (s, br, 2H), 4.43 (s, br, 1H), 4.08 (s, br, 5H). 13C{1H} NMR (101 MHz): 529 
139.9–121.5 (C, CH, Ar), 74.1 (d, JCP = 12.4, CH), 72.8 (d, JCP = 7.9, CH), 72.1 (d, JCP = 7.3, CH), 530 
71.9 (d, JCP = 8.4, CH), 69.9 (s, 5CH), 67.8 (d, JCP = 69.7, C). 31P {1H} NMR (162 MHz): +18.9 (s, 531 
br). HRMS: calcd for C28H22FePS ([M] + H − BH3), 477.0529; found, 477.0537. [α]D = –98.2°. 532 
4-TA-Me, (S)-methylphenyl(1-thianthrenyl)phosphineborane. The procedure was the same as that used 533 
to prepare 4-DBF-Me. Starting from 3-TA (200 mg, 0.5 mmol) and 1.6 M MeLi solution (0.7 mL, 1.1 534 
mmol) the desired phosphineborane was obtained as a white pasty solid. Yield: 166 mg (87%). 535 
1H NMR (400 MHz): 7.94 (ddd, J = 12.8, 8.0, 1.6, 1H), 7.71 (dt, J = 7.6, 1.6, 1H), 7.57 (dt, J = 11.2, 536 
1.6, 1H), 7.55 (dd, J = 11.2, 1.6, 4H), 7.44–7.36 (m, 2H), 7.23 (m, 1H), 7.16 (td, J = 7.6, 1.2, 1H), 7.06 537 
(dd, J = 7.6, 1.6, 1H), 2.09 (d, 2JHP = 10.0, 3H). 13C{1H} NMR (101 MHz): 140.7–126.3 (C, CH, Ar), 538 
11.8 (d, 1JCP = 40.5, CH3). 31P{1H} NMR (162 MHz): +15.9 (d, br, J ≈ 51). HRMS: calcd for 539 
C19H17BPS2 ([M] − H), 351.0602; found, 351.0602. [α]D = +115.8°. 540 
L1 (5-DBF-OMe), (R)-(4-dibenzofuranyl)methoxyphenylphosphine. Phosphinite-borane 3-DBF (240 541 
mg, 0.72 mmol) was dissolved in 5 mL of morpholine and the solution was stirred at 40 °C for 14 h. 542 
Morpholine was removed under vacuum and the gummy residue was purified by column 543 
chromatography (Al2O3, toluene) to yield the title product as a dense, colourless oil. Yield: 190 mg 544 
(81%). 545 
1H NMR (400 MHz): 7.98–7.93 (m, 3H), 7.64 (td, J = 8.0, 2.0, 1H), 7.58 (d, J = 8.0, 1H), 7.53 (m, 1H), 546 
7.49–7.42 (m, 2H), 7.40–7.31 (m, 4H), 3.80 (d, 3JHP = 14.0, 3H). 13C{1H} NMR (101 MHz): 156.2–547 
111.0 (C, CH, Ar), 57.3 (d, 2JCP = 20.6, CH3). 31P{1H} NMR (121 MHz): +106.8 (s). 548 
L2 (5-DBT-OMe), (R)-(4-dibenzothiophenyl)methoxyphenylphosphine. The procedure was the same as 549 
that used to prepare 5-DBF-OMe. Starting from 3-DBT (328 mg, 0.98 mmol) the desired phosphine-550 
borane was obtained as a colourless oil. Yield: 220 mg (70%). 551 
1H NMR (400 MHz): 8.19–8.13 (m, 3H), 7.88–7.83 (m, 2H), 7.65–7.57 (m, 2H), 7.53–7.43 (m, 3H), 552 
7.37–7.34 (m, 2H), 3.78 (d, 3JHP = 14.0, 3H). 13C{1H} NMR (101 MHz): 139.4–121.5 (C, CH, Ar), 553 
57.2 (d, 2JCP = 20.0, CH3). 31P{1H} NMR (162 MHz): +114.2 (s). 554 
L3 (5-TA-OMe), (R)-Methoxyphenyl(1-thianthrenyl)phosphine. The procedure was the same as that 555 
used to prepare 5-DBF-OMe. Starting from 3-TA (630 mg, 1.71 mmol) the desired phosphine-borane 556 
was obtained as a colourless oil. Yield: 510 mg (84%). 557 
1H NMR (400 MHz): 7.61–7.41 (m, 5H), 7.38–7.30 (m, 4H), 7.26–7.17 (m, 2H), 3.71 (d, 3JHP = 14.0, 558 
3H). 13C{1H} NMR (101 MHz): 142.3–127.4 (C, CH, Ar), 57.1 (d, 2JCP = 21.8, CH3). 31P{1H} NMR 559 
(162 MHz): +104.4 (s). 560 
L4 (5-DBTO2-OMe), (R)-(4-dibenzothiophenyl-S,S-dioxide) methoxyphenylphosphine. The procedure 561 
was the same as that used to prepare 5-DBF-OMe. Starting from 3-DBTO2 (200 mg, 0.54 mmol) the 562 
desired phosphine-borane was obtained as a white solid. Yield: 150 mg (78%). 563 
1H NMR (400 MHz): 7.82 (dq, J = 7.6, 0.4, 1H), 7.75–7.63 (m, 5H), 7.59 (tt, J = 8.0, 0.8, 1H), 7.56–564 
7.47 (m, 2H), 7.41–7.30 (m, 3H), 3.78 (d, 3JHP = 14.4, 3H). 13C{1H} NMR (101 MHz): 141.1–121.4 565 
(C, CH, Ar), 57.2 (d, 2JCP = 21.9, CH3). 31P{1H} NMR (162 MHz): +101.4 (s). 566 
L5 (5-DBF-Me), (S)-(4-dibenzofuranyl)methylphenylphosphine. The procedure was the same as that 567 
used to prepare 5-DBF-OMe. Starting from 4-DBF-Me (500 mg, 1.56 mmol) the desired phosphine-568 
borane was obtained as a colourless oil. Yield: 329 mg (69%). 569 
1H NMR (300 MHz): 8.00–7.92 (m, 2H), 7.62–7.54 (m, 3H), 7.51–7.43 (m, 2H), 7.40–7.30 (m, 5H), 570 
1.86 (d, 2JHP = 3.9, 3H). 13C{1H} NMR (101 MHz): 158.0–111.6 (C, CH, Ar), 11.1 (d, 1JCP = 12.8, 571 
CH3). 31P{1H} NMR (121 MHz): −37.0 (s) 572 
L6 (5-DBF-iPr), (S)-(4-dibenzofuranyl)isopropylphenylphosphine. The procedure was the same as that 573 
used to prepare 5-DBF-OMe. Starting from 4-DBF-iPr (185 mg, 0.56 mmol) the desired phosphine-574 
borane was obtained as a colourless oil. Yield: 120 mg (68%). 575 
1H NMR (300 MHz): 7.94 (d, J = 7.5, 2H), 7.67–7.52 (m, 4H), 7.45 (td, J = 7.2, 1.2, 1H), 7.37–7.29 (m, 576 
5H), 2.91 (dd, J = 7.2, 6.9, 1H), 1.16 (dd, J = 13.2, 6.9, 3H), 1.11 (dd, J = 13.2, 6.9, 3H). 13C{1H} NMR 577 
(101 MHz): 159.7–110.0 (C, CH, Ar), 22.4 (d, 1JCP = 6.7, CH), 19.9 (d, 2JCP = 7.1, CH3), 19.7 (d, 578 
2JCP = 8.8, CH3). 31P{1H} NMR (121 MHz): −10.7 (s). 579 
L7 (5-DBF-tBu), (S)-(tert-butyl)(4-dibenzofuranyl)phenylphosphine. The procedure was the same as 580 
that used to prepare 5-DBF-OMe. Starting from 4-DBF-tBu (600 mg, 1.73 mmol) the desired 581 
phosphine-borane was obtained as a colourless oil. Yield: 488 mg (85%). 582 
1H NMR (300 MHz): 7.97 (dd, J = 7.5, 1.2, 1H), 7.95 (ddd, J = 7.8, 1.5, 0.8, 1H), 7.68–7.57 (m, 4H), 583 
7.44 (td, J = 7.2, 1.5, 1H), 7.38–7.30 (m, 5H), 1.28 (d, 3JHP = 13.2, 9H). 31P{1H} NMR (121 MHz): 584 
+0.6 (s). 585 
L8 (5-DBF-Fc), (S)-(4-dibenzofuranyl)ferrocenylphenylphosphine. The procedure was the same as that 586 
used to prepare 5-DBF-OMe. Starting from 4-DBF-Fc (600 mg, 1.26 mmol) the desired phosphine-587 
borane was obtained as an orange solid. Yield: 490 mg (84%). 588 
1H NMR (400 MHz): 7.95 (dq, J = 7.6, 0.8 1H), 7.94 (ddd, J = 7.6, 1.2, 0.4, 1H), 7.57 (d, J = 8.0, 1H), 589 
7.48–7.41 (m, 3H), 7.35–7.29 (m, 4H), 7.27 (d, J = 7.2, 1H), 7.15 (m, 1H), 4.39 (m, 2H), 4.18 (m, 1H), 590 
4.15 (m, 1H), 4.08 (m, 5H). 13C{1H} NMR (101 MHz): 156.0–111.6 (C, CH, Ar), 73.1 (d, JCP = 15.0, 591 
CH), 73.0 (d, JCP = 15.4, CH), 70.9 (d, JCP = 4.0, CH), 70.7 (d, JCP = 4.0, CH), 69.1 (s, 5CH), 67.9 (s, 592 
C). 31P{1H} NMR (162 MHz): −32.1 (s). 593 
L9 (5-DBF-DBT), (S)-(4-dibenzofuranyl)(4-dibenzothiophenyl) phenylphosphine. Dibenzothiophene 594 
(210 mg, 1.1 mmol) was dissolved in 20 mL of THF in a Schlenk flask. The solution was cooled to −78 595 
°C and then 1.6 M n-BuLi solution in hexanes (0.7 mL, 1.1 mmol) was added using a syringe. The 596 
resulting brown solution was removed from the cold bath, left stirring at 0 °C for 5 h and recooled to 597 
−78 °C. At the same time phosphinite-borane 5-DBF-OMe (350 mg, 1.1 mmol) was dissolved in 20 mL 598 
of THF and the solution was cooled down to −78 °C. The content of the first flask was slowly 599 
transferred to the second Schlenk flask via cannula and the resulting mixture was stirred for 14 h. 600 
Around 20 mL of deoxygenated water were added to the brown-yellow solution and THF was 601 
evaporated. The white residue was extracted with dichloromethane (3 × 30 mL) under a nitrogen 602 
atmosphere and the combined organic phases were washed with deoxygenated water and dried with 603 
anhydrous sodium sulfate. The suspension was filtered under nitrogen and the solvent was evaporated to 604 
dryness, leaving a white pasty solid. 10 mL of morpholine were added and the solution was stirred at 605 
40°C for 14 h. Morpholine was removed under vacuum and the gummy residue was purified by column 606 
chromatography (Al2O3, toluene) to yield the title product as a pale brown solid. Yield: 307 mg (61%). 607 
1H NMR (400.1 MHz): 8.17 (m, 2H), 7.96 (m, 2H), 7.86 (m, 1H), 7.58 (d, J = 8.4, 1H), 7.46 (m, 7H), 608 
7.35 (m, 3H), 7.27 (t, J = 7.6, 1H), 7.10 (m, 1H), 7.02 (m, 1H). 31P{1H} NMR (162 MHz): −23.1 (s). 609 
HRMS: calcd for C30H20OPS ([M] + H), 459.0972; found, 459.0975. 610 
L10 (5-DBT-Me), (S)-(4-dibenzothiophenyl)methylphenylphosphine. The procedure was the same as 611 
that used to prepare 5-DBF-OMe. Starting from 4-DBT-Me (450 mg, 1.41 mmol) the desired phosphine-612 
borane was obtained as a colourless oil. Yield: 380 mg (88%). 613 
1H NMR (400 MHz): 8.17–8.13 (m, 2H), 7.84 (m, 1H), 7.51–7.42 (m, 6H), 7.35–7.31 (m, 3H), 1.78 (d, 614 
2JHP = 3.2, 3H). 13C{1H} NMR (101 MHz): 145.0–121.5 (C, CH, Ar), 11.2 (d, 1JCP = 13.1, CH3). 615 
31P{1H} NMR (162 MHz): −30.6 (s). 616 
L11 (5-DBT-iPr), (S)-(4-dibenzothiophenyl)isopropylphenylphosphine. The procedure was the same as 617 
that used to prepare 5-DBF-OMe. Starting from 4-DBT-iPr (490 mg, 1.41 mmol) the desired phosphine-618 
borane was obtained as a colourless oil. Yield: 400 mg (85%). 619 
1H NMR (400 MHz): 8.19–8.10 (m, 3H), 7.85 (m, 1H), 7.61–7.55 (m, 2H), 7.52–7.41 (m, 4H), 7.33–620 
7.29 (m, 2H), 2.70 (m, 1H), 1.18 (dd, 3JHP, 3JHH = 6.8, 2.4, 3H), 1.14 (dd, 3JHP, 3JHH = 6.8, 2.4, 621 
3H). 13C{1H} NMR (101 MHz): 147.2–121.5 (C, CH, Ar), 25.0 (d, 1JCP = 7.7, CH), 19.8 (d, 2JCP = 622 
6.7, CH3), 19.6 (d, 2JCP = 7.8, CH3). 31P{1H} NMR (162 MHz): −5.1 (s).  623 
L12 (5-DBT-Fc), (S)-(4-dibenzothiophenyl)ferrocenylphenylphosphine. The procedure was the same as 624 
that used to prepare 5-DBF-OMe. Starting from 4-DBT-Fc (350 mg, 0.71 mmol) the desired phosphine-625 
borane was obtained as an orange solid. Yield: 300 mg (89%). 626 
1H NMR (400 MHz): 8.14 (d, J = 4.4, 1H), 8.11 (d, J = 7.2, 1H), 7.80 (t, J = 4.8, 1H), 7.54–7.48 (m, 627 
2H), 7.45–7.38 (m, 3H), 7.35–7.30 (m, 3H), 7.22 (m, 1H), 4.45 (s, br, 1H), 4.41 (s, br, 1H), 4.38 (s, br, 628 
1H), 4.09 (s, br, 5H), 4.06 (s, br, 1H). 13C{1H} NMR (101 MHz): 144.6–121.6 (C, CH, Ar), 74.2 (d, 629 
JCP = 4.2, C), 73.9 (d, JCP = 23.2, CH), 72.4 (d, JCP = 6.8, CH), 71.2 (d, JCP = 5.9, CH), 70.7 (d, JCP 630 
= 2.4, CH), 69.2 (s, 5CH). 31P{1H} NMR (162 MHz): −20.5 (s). 631 
L13 (5-TA-Me), (S)-methylphenyl(1-thianthrenyl)phosphine. The procedure was the same as that used 632 
to prepare 5-DBF-OMe. Starting from 4-TA-Me (350 mg, 0.99 mmol) the desired phosphine-borane 633 
was obtained as colourless, dense oil. Yield: 280 mg (83%). 634 
1H NMR (400 MHz): 7.50–7.41 (m, 4H), 7.36–7.33 (m, 3H), 7.26–7.18 (m, 4H), 7.15 (ddd, J = 7.6, 4.4, 635 
1.2, 1H), 1.65 (d, 2JHP = 4.8, 3H). 13C{1H} NMR (101 MHz): 140.8–126.6 (C, CH, Ar), 12.3 (d, 1JCP 636 
= 14.6, CH3). 31P{1H} NMR (162 MHz): −32.1 (s). 637 
 638 
Synthesis of the Ru complexes 639 
Ru1, [RuCl2(η6-p-cymene)(L1)]. Phosphinite L1 (214 mg, 0.70 mmol) was dissolved in 20 mL of 640 
dichloromethane, Ru dimer D1 (150 mg, 0.25 mmol) was added and the dark red solution was stirred for 641 
1 h. The solvent was removed under vacuum and the residue was recrystallised in 642 
dichloromethane/hexane to furnish the title product as a dark red solid. Yield: 246 mg (80%). 643 
IR: 3051, 2958, 2869, 1580, 1469, 1450, 1400, 1185, 1109, 1032, 845, 804, 757, 696, 562. 1H NMR 644 
(400 MHz): 8.37 (ddd, J = 11.2, 7.6, 1.2, 1H), 8.05–8.00 (m, 3H), 7.93 (dt, J = 7.6, 1.2, 1H), 7.43–7.32 645 
(m, 7H), 5.41 (d, J = 6.6, 1H), 5.37 (d, J = 6.0, 1H), 5.33 (d, J = 6.0, 1H), 5.05 (d, J = 6.0, 1H), 3.63 (d, 646 
3JHP = 12.0, 3H), 2.72 (sept, 3JHH = 6.8, 1H), 1.97 (s, 3H), 1.01 (d, 3JHH = 6.8, 3H), 0.88 (d, 3JHH = 647 
6.8, 3H). 13C{1H} NMR (101 MHz): 155.6–111.6 (C, CH, Ar), 110.9 (d, 2JCP = 1.7, C), 96.5 (s, C), 648 
92.6 (d, 2JCP = 5.6, CH), 90.3 (d, 2JCP = 3.9, CH), 88.3 (d, 2JCP = 7.2, CH), 86.5 (d, 2JCP = 5.6, CH), 649 
55.1 (d, 2JCP = 5.1, CH3), 30.0 (s, CH), 21.8 (s, CH3), 21.0 (s, CH3), 17.6 (s, CH3). 31P{1H} NMR 650 
(121 MHz): +112.7 (s). Anal.: calcd for C29H29Cl2O2PRu, C 56.87%, H 4.77%; found, C 57.29%, H 651 
5.03%. 652 
Ru2, [RuCl2(η6-p-cymene)(L2)]. The procedure was the same as that followed to prepare Ru1. Starting 653 
from L2 (220 mg, 0.68 mmol) and Ru dimer D1 (149 mg, 0.24 mmol), the desired complex was 654 
obtained as a dark red solid. Yield: 217 mg (72%). IR: 3053, 2958, 2870, 1439, 1375, 1103, 1028, 756, 655 
695, 554. 656 
1H NMR (300 MHz): 8.34 (ddd, J = 13.2, 7.5, 0.9, 1H), 8.23 (dt, J = 8.0, 1.5, 1H), 8.18–8.14 (m, 1H), 657 
7.99–7.93 (m, 2H), 7.84–7.81 (m, 1H), 7.53–7.45 (m, 3H), 7.39–7.32 (m, 3H), 5.44 (d, J = 6.0, 1H), 658 
5.36 (d, J = 6.9, 1H), 5.33 (d, J = 7.8, 1H), 5.24 (d, J = 6.0, 1H), 3.70 (d, 3JHP = 11.7, 3H), 2.70 (sept, 659 
3JHH = 7.2, 1H), 1.89 (s, 3H), 1.02 (d, 3JHH = 6.9, 3H), 1.00 (d, 3JHH = 6.9, 3H). 13C{1H} NMR 660 
(101 MHz): 140.0–121.4 (C, CH, Ar), 111.6 (d, 2JCP = 1.1, C), 96.9 (s, C), 91.7 (d, 2JCP = 4.1, CH), 661 
91.4 (d, 2JCP = 4.6, CH), 87.5 (d, 2JCP = 6.6, CH), 87.2 (d, 2JCP = 5.9, CH), 54.6 (d, 2JCP = 3.6, 662 
CH3), 30.1 (s, CH), 21.7 (s, CH3), 21.5 (s, CH3), 17.5 (s, CH3). 31P{1H} NMR (121 MHz): +118.3 (s). 663 
Anal.: calcd for C29H29Cl2OPRuS, C 55.42%, H 4.65%, S 5.10%; found, C 55.97%, H 5.01%, S 664 
4.89%. 665 
Ru3, [RuCl2(η6-p-cymene)(L3)]. The procedure was the same as that followed to prepare Ru1. Starting 666 
from L3 (270 mg, 0.76 mmol) and Ru dimer D1 (186 mg, 0.30 mmol), the desired complex was 667 
obtained as a dark red solid. Yield: 217 mg (55%). 668 
IR: 3052, 2959, 2869, 1470, 1448, 1435, 1378, 1109, 1029, 752, 694, 550. 1H NMR (400 MHz): 8.30 669 
(dd, J = 11.6, 7.6, 1H), 7.84 (t, J = 9.2, 2H), 7.64 (d, J = 7.6, 1H), 7.46–7.34 (m, 5H), 7.21 (td, J = 7.2, 670 
1.2, 1H), 7.11 (td, J = 7.6, 1.2, 1H), 7.00 (dd, J = 7.6, 1.2, 1H), 5.41 (d, J = 6.4, 1H), 5.31 (d, J = 6.0, 671 
1H), 5.27 (d, J = 6.0, 1H), 5.18 (d, J = 5.6, 1H), 3.61 (d, 3JHP = 11.6, 3H), 2.63 (sept, 3JHH = 6.8, 1H), 672 
1.93 (s, 3H), 0.92 (d, 3JHH = 7.2, 3H), 0.86 (d, 3JHH = 7.2, 3H). 31P{1H} NMR (162 MHz): +110.2 673 
(s). HRMS: calcd for C29H29ClOPRuS2 ([M] − Cl), 625.0123; found, 625.0126. 674 
Ru4, [RuCl2(η6-p-cymene)(L4)]. The procedure was the same as that followed to prepare Ru1. Starting 675 
from L4 (70 mg, 0.20 mmol) and Ru dimer D1 (48 mg, 0.08 mmol), the desired complex was obtained 676 
as a dark red solid. Yield: 70 mg (68%). 677 
IR: 3060, 2959, 2869, 1446, 1436, 1387, 1308, 1154, 1095, 1045, 815, 764, 721, 701, 584, 568, 468. 1H 678 
NMR (400 MHz): 8.13 (tt, J = 8.4, 1.6, 2H), 7.98 (ddd, J = 13.2, 7.6, 0.8, 1H), 7.91 (d, J = 6.8, 1H), 7.86 679 
(t, J = 7.6, 2H), 7.71 (td, J = 7.6, 1.2, 1H), 7.64 (td, J = 7.6, 0.8, 1H), 7.52 (td, J = 7.6, 2.0, 1H), 7.37–680 
7.27 (m, 3H), 5.68 (d, J = 6.0, 1H), 5.62 (dd, J = 6.4, 1.2, 1H), 5.50 (d, J = 6.0, 1H), 5.31 (d, J = 6.0, 681 
1H), 3.72 (d, 3JHP = 11.6, 3H), 2.72 (sept, 3JHH = 6.8, 1H), 1.87 (s, 3H), 1.17 (d, 3JHH = 6.8, 3H), 682 
0.97 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 141.9–121.2 (C, CH, Ar), 112.1 (s, C), 97.4 (s, 683 
C), 93.8 (d, 2JCP = 5.4, CH), 90.9 (d, 2JCP = 3.8, CH), 87.6 (d, 2JCP = 6.3, CH), 86.7 (d, 2JCP = 5.9, 684 
CH), 54.2 (d, 2JCP = 4.0, CH3), 30.1 (s, CH), 22.3 (s, CH3), 21.1 (s, CH3), 17.5 (s, CH3). 31P{1H} 685 
NMR (162 MHz): +117.0 (s). Anal.: calcd for C29H29Cl2O3PRuS, C 52.73%, H 4.42%, S 4.85%; 686 
found, C 51.15%, H 4.51%, S 4.42%. 687 
Ru5, [RuCl2(η6-p-cymene)(L5)]. The procedure was the same as that followed to prepare Ru1. Starting 688 
from L5 (185 mg, 0.64 mmol) and Ru dimer D1 (162 mg, 0.26 mmol), the desired complex was 689 
obtained as a dark red solid. Yield: 201 mg (65%). 690 
IR: 3049, 2958, 2919, 2868, 1583, 1469, 1449, 1399, 1185, 1109, 1057, 898, 843, 802, 755, 725, 696, 691 
556, 424. 1H NMR (300 MHz): 8.11 (dt, J = 7.8, 1.2, 1H), 8.04–8.00 (m, 1H), 7.96 (ddd, J = 7.8, 1.5, 692 
0.9, 1H), 7.89 (ddd, J = 11.1, 7.8, 1.2, 1H), 7.78–7.71 (m, 2H), 7.59–7.56 (m, 1H), 7.52–7.31 (m, 5H), 693 
5.59 (d, J = 6.3, 1H), 5.49 (d, J = 6.3, 1H), 5.47 (m, 1H), 4.76 (d, J = 5.7, 1H), 2.54 (sept, 3JHH = 6.9, 694 
1H), 2.06 (s, 3H), 2.04 (d, 2JHP = 11.4, 3H), 0.90 (d, 3JHH = 6.9, 3H), 0.38 (d, 3JHH = 6.9, 3H). 13C 695 
{1H} NMR (101 MHz): 156.1–111.6 (C, CH, Ar), 107.8 (s, C), 94.2 (s, C), 93.8 (d, 2JCP = 6.7, CH), 696 
89.6 (d, 2JCP = 8.8, CH), 86.4 (d, 2JCP = 2.6, CH), 81.4 (d, 2JCP = 3.2, CH), 29.8 (s, CH), 22.8 (s, 697 
CH3), 19.1 (s, CH3), 17.5 (s, CH3), 12.1 (d, 1JCP = 37.4, CH3). 31P{1H} NMR (121 MHz): +15.2 (s). 698 
Anal.: calcd for C29H29Cl2OPRu, C 58.39%, H 4.90%; found, C 60.59%, H 5.04%. 699 
Ru6, [RuCl2(η6-p-cymene)(L6)]. The procedure was the same as that followed to prepare Ru1. Starting 700 
from L6 (166 mg, 0.52 mmol) and Ru dimer D1 (114 mg, 0.19 mmol), the desired complex was 701 
obtained as a dark red solid. Yield: 145 mg (62%). 702 
IR: 3054, 2958, 2925, 2867, 1581, 1469, 1449, 1434, 1398, 1264, 1182, 1109, 1039, 844, 802, 759, 699, 703 
533, 516. 1H NMR (400 MHz): 8.10 (dt, J = 7.6, 1.2, 1H), 8.04 (d, J = 8.0, 1H), 8.01–7.94 (m, 3H), 704 
7.51–7.38 (m, 7H), 5.23 (d, J = 6.0, 2H), 5.11 (d, J = 6.0, 1H), 4.51 (d, J = 5.6, 1H), 3.71 (m, 1H), 2.66 705 
(sept, 3JHH = 7.2, 1H), 1.89 (s, 3H), 1.10 (dd, J = 18.0, 7.2, 3H), 0.97 (dd, J = 14.0, 6.8, 3H), 0.92 (d, 706 
3JHH = 6.8, 3H), 0.68 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 155.3–111.7 (C, CH, Ar), 707 
109.2 (s, C), 93.9 (d, 2JCP = 4.5, C), 93.6 (s, CH), 88.9 (d, 2JCP = 2.4, CH), 86.1 (d, 2JCP = 7.4, CH), 708 
83.4 (d, 2JCP = 4.6, CH), 29.9 (s, CH), 26.2 (d, 1JCP = 23.5, CH), 22.3 (s, CH3), 20.3 (s, CH3), 19.1 (d, 709 
2JCP = 6.2, CH3), 18.7 (s, CH3), 17.5 (s, CH3). 31P{1H} NMR (121 MHz): +21.5 (s). Anal.: calcd for 710 
C31H33Cl2OPRu, C 59.62%, H 5.33%; found, C 59.08%, H 5.64%. 711 
Ru8, [RuCl2(η6-p-cymene)(L8)]. The procedure was the same as that followed to prepare Ru1. Starting 712 
from L8 (180 mg, 0.39 mmol) and Ru dimer D1 (96 mg, 0.16 mmol), the desired complex was obtained 713 
as a dark red solid. Yield: 180 mg (75%). 714 
IR: 3051, 2957, 2924, 2868, 1624, 1579, 1469, 1449, 1435, 1398, 1306, 1263, 1183, 1158, 1108, 1058, 715 
1028, 1002, 844, 821, 801, 755, 699, 560, 458. 1H NMR (400 MHz): 8.03–8.00 (m, 2H), 7.96 (d, J = 716 
8.0, 1H), 7.93 (d, J = 7.2, 1H), 7.74 (dd, J = 10.8, 7.6, 1H), 7.53–7.47 (m, 1H), 7.46–7.41 (m, 3H), 7.40–717 
7.29 (m, 3H), 5.56 (d, J = 6.4, 1H), 5.38 (d, J = 6.8, 1H), 5.37–5.35 (m, 1H), 4.97 (m, 1H), 4.61 (d, J = 718 
5.6, 1H), 4.38 (m, 1H), 4.34 (m, 1H), 4.26 (m, 1H), 3.66 (s, 5H), 2.55 (sept, 3JHH = 6.8, 1H), 2.03 (s, 719 
3H), 0.89 (d, 3JHH = 7.2, 3H), 0.33 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 155.0–111.4 (C, 720 
CH, Ar), 109.1 (s, C), 94.6 (d, 2JCP = 4.4, C), 93.8 (s, CH), 88.9 (d, 2JCP = 9.1, CH), 87.8 (s, CH), 81.5 721 
(s, CH), 78.0 (d, JCP = 12.1, CH), 75.0 (d, 1JCP = 54.0, C), 74.3 (d, 2JCP = 8.2, CH), 70.0 (s, ov, 6CH), 722 
69.6 (d, JCP = 8.1, CH), 29.6 (s, CH), 22.6 (s, CH3), 19.0 (s, CH3), 17.1 (s, CH3). 31P {1H} NMR (162 723 
MHz): +15.8 (s). Anal.: calcd for C38H35Cl2FeOPRu, C 59.55%, H 4.60%; found, C 59.59%, H 724 
5.00%. 725 
Ru9, [RuCl2(η6-p-cymene)(L9)]. The procedure was the same as that followed to prepare Ru1. Starting 726 
from L9 (140 mg, 0.31 mmol) and Ru dimer D1 (74 mg, 0.12 mmol), the desired complex was obtained 727 
as a dark red solid. Yield: 101 mg (55%). 728 
1H NMR (400 MHz): 8.43 (dd, J = 13.2, 7.6 1H), 8.30–8.22 (m, 3H), 8.16–8.07 (m, 3H), 7.94 (d, J = 729 
6.8, 1H), 7.59 (d, J = 6.4, 1H), 7.55 (d, J = 7.6, 1H), 7.43–7.20 (m, 9H), 5.27 (d, J = 6.0, 2H), 5.20 (d, J 730 
= 6.0, 1H), 5.04 (d, J = 6.0, 1H), 2.80 (sept, 3JHH = 6.8, 1H), 1.90 (s, 3H), 0.94 (d, 3JHH = 6.8, 3H), 731 
0.86 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 155.9–120.7 (C, CH, Ar), 111.5 (s, C), 95.7 (s, 732 
C), 91.1 (d, 2JCP = 2.4, CH), 89.7 (d, 2JCP = 3.4, CH), 86.2 (d, 2JCP = 6.5, CH), 85.8 (d, 2JCP = 5.7, 733 
CH), 30.0 (s, CH), 21.6 (s, CH3), 21.3 (s, CH3), 17.6 (s, CH3). 31P{1H} NMR (162 MHz): +19.8 (s). 734 
HRMS: calcd for C40H33ClOPRuS ([M] − Cl), 729.0716; found, 729.0745. 735 
Ru10, [RuCl2(η6-p-cymene)(L10)]. The procedure was the same as that followed to prepare Ru1. 736 
Starting from L10 (190 mg, 0.62 mmol) and Ru dimer D1 (140 mg, 0.23 mmol), the desired complex 737 
was obtained as a dark red solid. Yield: 251 mg (89%). 738 
IR: 3051, 2958, 2868, 2838, 1438, 1374, 1103, 1027, 817, 755, 694, 554. 1H NMR (400 MHz): 8.28 (dt, 739 
J = 7.6, 1.6, 1H), 8.19 (m, 1H), 8.15 (ddd, J = 12.4, 7.6, 1.2, 1H), 7.79–7.74 (m, 2H), 7.70 (dd, J = 7.2, 740 
2.0, 1H), 7.61 (td, J = 7.6, 1.6, 1H), 7.54–7.42 (m, 5H), 5.64 (d, J = 5.6, 1H), 5.57 (d, J = 6.0, 1H), 5.34 741 
(d, J = 6.0, 1H), 5.17 (d, J = 5.6, 1H), 2.55 (sept, 3JHH = 7.2, 1H), 2.08 (d, 2JHP = 9.6, 3H), 2.07 (s, 742 
3H), 0.83 (d, 3JHH = 7.2, 3H), 0.57 (d, 3JHH = 7.2, 3H). 13C{1H} NMR (101 MHz): 140.7–121.7 (C, 743 
CH, Ar), 107.2 (s, C), 94.5 (s, C), 91.7 (d, 2JCP = 5.8, CH), 88.7 (d, 2JCP = 6.9, CH), 88.1 (d, 2JCP = 744 
3.7, CH), 83.1 (d, 2JCP = 4.6, CH), 29.8 (s, CH), 22.0 (s, CH3), 20.0 (s, CH3), 17.5 (s, CH3), 11.2 (d, 745 
1JCP = 37.1, CH3). 31P{1H} NMR (162 MHz): +22.6 (s). Anal.: calcd for C29H29Cl2PRuS, C 746 
56.86%, H 4.77%, S 5.24%; found, C 56.69%, H 5.07%, S 5.26%. 747 
Ru11, [RuCl2(η6-p-cymene)(L11)]. The procedure was the same as that followed to prepare Ru1. 748 
Starting from L11 (400 mg, 1.20 mmol) and Ru dimer D1 (244 mg, 0.40 mmol), the desired complex 749 
was obtained as a dark red solid. Yield: 405 mg (79%). 750 
IR: 3044, 2959, 2923, 2866, 1467, 1435, 1371, 1102, 1034, 801, 752, 704, 546, 528. 1H NMR (400 751 
MHz): 8.28 (d, J = 8.0, 1H), 8.21 (d, J = 9.2, 1H), 7.99 (m, br, 2H), 7.78 (m, 1H), 7.62–7.57 (m, 3H), 752 
7.53–7.47 (m, 4H), 5.42 (d, J = 6.0, 2H), 4.94 (d, J = 6.0, 1H), 4.67 (d, J = 5.6, 1H), 3.76 (m, 1H), 2.71 753 
(sept, 3JHH = 7.2, 1H), 1.86 (s, 3H), 1.07–1.02 (m, 6H), 1.01 (dd, 3JHP = 15.6, 3JHH = 6.8, 3H), 0.78 754 
(d, 3JHH = 7.2, 3H). 13C{1H} NMR (101 MHz): 141.0–121.6 (C, CH, Ar), 108.4 (s, C), 94.4 (s, br, C), 755 
93.2 (s, br, CH), 88.3 (d, 2JCP = 3.9, CH), 88.3 (d, 2JCP = 3.6, CH), 85.5 (s, br, CH), 85.0 (s, br, CH), 756 
29.8 (s, CH), 25.1 (d, 1JCP = 22.7, CH), 22.2 (s, CH3), 21.0 (s, CH3), 19.9 (s, CH3), 19.0 (s, CH3), 17.6 757 
(s, CH3). 31P{1H} NMR (162 MHz): +25.4 (s, br). Anal.: calcd for C31H33Cl2PRuS, C 58.12%, H 758 
5.19%, S 5.00%; found, C 57.92%, H 5.47%, S 4.64%. 759 
Ru12, [RuCl2(η6-p-cymene)(L12)]. The procedure was the same as that followed to prepare Ru1. 760 
Starting from L12 (80 mg, 0.17 mmol) and Ru dimer D1 (42 mg, 0.07 mmol), the desired complex was 761 
obtained as a dark red solid. Yield: 78 mg (73%). 762 
IR: 2960, 1636, 1436, 1401, 1372, 1158, 1106, 1030, 754, 694, 549, 492. 1H NMR (400 MHz): 8.21–763 
8.16 (m, 2H), 8.09 (s, br, 1H), 7.80–7.72 (m, 2H), 7.55 (m, 1H), 7.49–7.45 (m, 6H), 5.47 (d, J = 6.4, 764 
1H), 5.33 (d, J = 6.0, 1H), 5.21 (d, J = 6.4, 1H), 5.06 (d, J = 6.0, 1H), 5.01 (s, 1H), 4.46 (s, 1H), 4.42 (s, 765 
1H), 4.35 (s, 1H), 3.69 (s, 5H), 2.53 (sept, 3JHH = 7.2, 1H), 1.95 (s, 3H), 0.86 (d, 3JHH = 7.2, 3H), 0.55 766 
(d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 140.5–121.5 (C, CH, Ar), 108.9 (s, C), 95.0 (s, C), 767 
92.8 (s, br, CH), 88.7 (s, br, CH), 88.3 (s, br, CH), 82.6 (s, br, CH), 79.1 (d, JCP = 15.9, CH), 74.1 (s, br, 768 
CH), 70.6 (s, br, CH), 70.3 (s, 5CH), 69.7 (m, br, CH), 29.7 (s, CH), 22.4 (s, CH3), 19.9 (s, br, CH3), 769 
17.2 (s, CH3). 31P{1H} NMR (162 MHz): +20.6 (s). Anal.: calcd for C38H35Cl2FePRuS, C 58.32%, H 770 
4.51%, S 4.10%; found, C 56.75%, H 4.75%, S 3.76%. 771 
Ru13, [RuCl2(η6-p-cymene)(L13)]. The procedure was the same as that followed to prepare Ru1. 772 
Starting from L13 (180 mg, 0.53 mmol) and Ru dimer D1 (125 mg, 0.20 mmol), the desired complex 773 
was obtained as a dark red solid. Yield: 250 mg (97%). 774 
1H NMR (400 MHz): 7.97 (dd, J = 12.0, 8.4, 2H), 7.71–7.66 (m, 2H), 7.52–7.44 (m, 4H), 7.37 (tt, J = 775 
8.0, 1.6, 1H), 7.28 (d, J = 7.6, 1H), 7.18 (t, J = 7.6, 1H), 7.12 (d, J = 8.0, 1H), 5.63 (d, J = 6.0, 2H), 5.45 776 
(d, J = 6.4, 1H), 5.19 (d, J = 5.2, 1H), 2.47 (sept, 3JHH = 7.2, 1H), 2.15 (s, 3H), 2.01 (d, 2JHP = 10.8, 777 
3H), 0.81 (d, 3JHH = 7.2, 3H), 0.29 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 138.9–126.2 (C, 778 
CH, Ar), 106.5 (s, C), 95.1 (s, C), 93.7 (s, br, CH), 91.0 (s, br, CH), 85.6 (s, CH), 81.3 (s, CH), 29.6 (s, 779 
CH), 22.7 (s, CH3), 19.1 (s, CH3), 17.7 (s, CH3), 13.5 (d, 1JCP = 37.2, CH3). 31P{1H} NMR (162 780 
MHz): +24.6 (s). Anal.: calcd for C29H29Cl2PRuS2, C 54.03%, H 4.54%, S 9.95%; found, C 53.28%, 781 
H 4.96%, S 9.50%.  782 
Ru6*, [RuCl2(η6-methyl benzoate)(L6)]. Phosphine L6 (60 mg, 0.19 mmol) was dissolved in 20 mL of 783 
dichloromethane, Ru dimer D2 (48 mg, 0.077 mmol) was added and the dark suspension was stirred for 784 
1 h and filtered. The solvent was removed under vacuum and the residue was recrystallized in 785 
dichloromethane/hexane to furnish the title product as a brown solid. Yield: 87 mg (87%). 786 
IR: 3039, 2959, 2869, 1728 ν(CvO), 1625, 1583, 1470, 1450, 1435, 1400, 1294, 1277, 1185, 1110, 845, 787 
803, 759, 698. 1H NMR (400 MHz): 8.14 (dt, J = 7.6, 1.6, 1H), 8.04 (d, J = 7.2, 2H), 7.96 (d, J = 7.2 788 
1H), 7.93 (d, J = 8.8 1H), 7.52–7.39 (m, 7H), 6.43 (d, J = 6.4, 1H), 6.31 (d, J = 5.6, 1H), 5.52 (m, 1H), 789 
4.96 (t, J = 6.0, 1H), 4.72 (t, J = 6.0, 1H), 3.87 (s, 3H), 3.81 (m, 1H), 1.13 (dd, J = 18.0, 7.2, 3H), 1.03 790 
(dd, J = 15.6, 7.2, 3H). 13C{1H} NMR (101 MHz): 167.1 (s, CvO), 164.5 (s, CvO), 155.3–111.8 (C, 791 
CH, Ar), 96.6 (s, CH), 94.4 (s, CH), 90.7 (s, CH), 85.5 (s, CH), 83.8 (s, CH), 53.2 (s, CH3), 52.1 (s, 792 
CH3), 27.0 (d, 1JCP = 24.6, CH), 19.5 (d, 2JCP = 4.9, CH3), 19.0 (s, CH3). 31P{1H} NMR (162 MHz): 793 
+25.8 (s). Anal.: calcd for C29H27Cl2O3PRu, C 55.60%, H 4.34%; found, C 54.91%, H 4.34%. 794 
Ru9*, [RuCl2(η6-methyl benzoate)(L9)]. The procedure was the same as that followed to prepare Ru6*. 795 
Starting from L9 (200 mg, 0.44 mmol) and Ru dimer D2 (90 mg, 0.15 mmol), the desired complex was 796 
obtained as a brownish solid. Yield: 140 mg (63%). 797 
IR: 3083, 3073, 2951, 1728 ν(CvO), 1618, 1581, 1469, 1449, 1435, 1400, 1374, 1281, 1187, 1110, 846, 798 
802, 755. 1H NMR (400 MHz): 8.36 (d, J = 8.0, 1H), 8.19 (d, J = 6.8, 1H), 8.13 (d, J = 8.0, 1H), 8.07 799 
(dd, J = 13.0, 7.6, 1H), 8.04–7.95 (m, 3H), 7.78 (dd, J = 13.2, 8.0, 1H), 7.63 (d, J = 7.6, 1H), 7.58 (dd, J 800 
= 8.0, 2.0, 1H), 7.47–7.31 (m, 7H), 7.28–7.21 (m, 2H), 6.53 (d, J = 6.4, 1H), 6.48 (d, J = 6.0, 1H), 5.49 801 
(tt, J = 9.6, 4.8, 1H), 5.20 (t, J = 6.0, 1H), 5.03 (t, J = 5.6, 1H), 3.95 (s, 3H). 13C{1H} NMR (101 MHz): 802 
167.1 (s, CvO), 156.2–111.4 (C, CH, Ar), 95.89 (s, CH), 95.85 (s, CH), 89.2 (s, CH), 85.3 (s, CH), 84.4 803 
(s, CH), 53.3 (s, CH3), 52.1 (s, CH3). 31P{1H} NMR (162 MHz): +22.4 (s). HRMS: calcd for 804 
C38H27ClO3PRuS ([M] − Cl), 731.0151; found, 731.0144. 805 
Ru11*, [RuCl2(η6-methyl benzoate)(L11)]. The procedure was the same as that followed to prepare 806 
Ru6*. Starting from L11 (214 mg, 0.64 mmol) and Ru dimer D2 (150 mg, 0.24 mmol), the desired 807 
complex was obtained as a brown solid. Yield: 246 mg (80%). 808 
IR: 3036, 2952, 2866, 1730 ν(CvO), 1433, 1372, 1293, 1277, 1106, 760, 695, 545, 516. 1H NMR (400 809 
MHz): 8.31 (d, J = 9.2, 1H), 8.22 (m, 1H), 8.03 (d, J = 9.2, 1H), 8.01 (d, J = 8.8, 1H), 7.93 (dd, J = 10.8, 810 
8.0 1H), 7.80 (m, 1H), 7.63–7.56 (m, 2H), 7.52–7.46 (m, 4H), 6.45 (d, J = 6.0, 1H), 6.26 (d, J = 6.0, 1H), 811 
5.33 (m, 1H), 5.20 (t, J = 6.0, 2H), 3.91 (s, 3H), 3.82 (m, 1H), 1.15 (dd, J = 14.4, 6.8, 3H), 1.07 (dd, J = 812 
18.0, 6.8, 3H). 13C{1H} NMR (101 MHz): 167.1 (CvO), 164.4 (CvO), 139.4–121.6 (C, CH, Ar), 95.1 813 
(d, 2JCP = 3.5, CH), 94.5 (d, 2JCP = 3.8, CH), 89.5 (s, CH), 85.2 (d, 2JCP = 3.6, CH), 84.9 (d, 2JCP = 814 
2.0, CH), 53.3 (s, CH3), 52.1 (s, CH3), 25.7 (d, 1JCP = 24.2, CH), 19.3 (d, 2JCP = 6.2, CH3), 18.7 (s, 815 
CH3). 31P{1H} NMR (162 MHz): +31.3 (s). Anal.: calcd for C29H27Cl2O2PRuS, C 54.21%, H 816 
4.23%, S 4.99%; found, C 54.17%, H 4.39%, S 4.98%. 817 
Ru13*, [RuCl2(η6-methyl benzoate)(L13)]. The procedure was the same as that followed to prepare 818 
Ru6*. Starting from L13 (200 mg, 0.59 mmol) and Ru dimer D2 (134 mg, 0.22 mmol), the desired 819 
complex was obtained as a dark red solid. Yield: 213 mg (76%). 820 
IR: 3053, 2950, 1728 ν(CvO), 1434, 1377, 1110, 896, 749, 503. 1H NMR (400 MHz): 8.00 (ddd, J = 821 
12.4, 7.6, 1.2, 1H), 7.74 (d, J = 7.6, 1H), 7.69–7.64 (m, 2H), 7.52–7.41 (m, 5H), 7.27 (m, 1H), 7.21–7.13 822 
(m, 2H), 6.41 (d, J = 6.0, 1H), 6.35 (d, J = 5.6, 1H), 5.54 (m, 1H), 5.42 (d, J = 5.6, 1H), 5.39 (d, J = 5.6, 823 
1H), 3.83 (s, 3H), 2.14 (d, 2JHP = 11.6, 3H). 31P{1H} NMR (162 MHz): +25.4 (s). HRMS: calcd for 824 
C27H23ClO2PRuS2 ([M] − Cl), 610.9603; found, 610.9595. 825 
Ru2′, [RuCl(η6-p-cymene)(κ2P,S-L2)]PF6. Complex Ru2 (56 mg, 0.089 mmol) was dissolved in 20 mL 826 
of dichloromethane, thallium hexafluorophosphate (34 mg, 0.094 mmol) was added and the reddish 827 
suspension was stirred for 2 h. Water (20 mL) was added and the mixture was extracted with 828 
dichloromethane (3 × 10 mL). The combined organic phases were washed with water, dried with 829 
anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. The crude yellow 830 
product was recrystallised in dichloromethane/hexane. Yield: 53 mg (81%). 831 
IR: 3089, 2968, 2876, 1618, 1471, 1438, 1391, 1108, 1020, 839 ν(PF6 −), 762, 558. 1H NMR (400 832 
MHz): 8.21 (dd, J = 6.0, 3.2, 1H), 8.11 (dd, J = 7.6, 1.6, 1H), 8.06 (dd, J = 6.4, 3.2, 1H), 7.75–7.71 (m, 833 
2H), 7.66–7.54 (m, 6H), 7.48 (t, J = 8.0, 1H), 6.34 (d, J = 6.4, 1H), 6.14 (d, J = 6.4, 1H), 6.09 (d, J = 6.0, 834 
1H), 6.04 (d, J = 6.0, 1H), 3.89 (d, 3JHP = 12.4, 3H), 2.56 (sept, 3JHH = 6.8, 1H), 2.06 (s, 3H), 1.13 (d, 835 
3JHH = 6.8, 3H), 0.83 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 152.9–123.9 (C, CH, Ar), 836 
114.2 (s, C), 103.1 (s, C), 92.8 (d, 2JCP = 6.0, CH), 92.2 (d, 2JCP = 3.4, CH), 91.8 (d, 2JCP = 4.1, CH), 837 
88.4 (d, 2JCP = 2.7, CH), 56.6 (d, 2JCP = 12.1, CH3), 31.4 (s, CH), 22.1 (s, CH3), 20.7 (s, CH3), 18.7 838 
(s, CH3). 31P{1H} NMR (162 MHz): +138.7 (s). HRMS: calcd for C29H29ClOPRuS ([M] − PF6), 839 
593.0403; found, 593.0406. 840 
Ru3′, [RuCl(η6-p-cymene)(κ2P,S-L3)]PF6. The procedure was the same as that followed to prepare 841 
Ru2′. Starting from Ru3 (100 mg, 0.15 mmol) and TlPF6 (56 mg, 0.16 mmol), the desired complex was 842 
obtained as a pale red solid. Yield: 95 mg (82%). 843 
IR: 3085, 2967, 1471, 1437, 1389, 1146, 1108, 1018, 840 ν(PF6−), 756, 705, 558. 1H NMR (400 MHz): 844 
7.97 (dd, J = 8.0, 1.2, 1H), 7.86–7.78 (m, 3H), 7.67 (dd, J = 7.6, 1.2, 1H), 7.62–7.51 (m, 6H), 7.46 (td, J 845 
= 7.6, 1.2, 1H), 6.54 (d, J = 6.4, 1H), 6.43 (d, J = 6.0, 1H), 6.30 (dd, J = 6.4, 1.2, 1H), 6.19 (d, J = 6.0, 846 
1H), 3.62 (d, 3JHP = 11.6, 3H), 2.57 (sept, 3JHH = 6.8, 1H), 2.01 (s, 3H), 1.14 (d, 3JHH = 6.8, 3H), 847 
0.84 (d, 3JHH = 6.8, 3H). 13C{1H} NMR (101 MHz): 140.5–127.4 (C, CH, Ar), 114.2 (s, C), 103.2 (s, 848 
C), 95.2 (d, 2JCP = 4.9, CH), 94.5 (d, 2JCP = 3.7, CH), 94.4 (d, 2JCP = 5.6, CH), 90.8 (d, 2JCP = 3.3, 849 
CH), 56.2 (d, 2JCP = 12.5, CH3), 31.2 (s, CH), 22.1 (s, CH3), 20.8 (s, CH3), 18.3 (s, CH3). 31P{1H} 850 
NMR (162 MHz): +145.5 (s). Anal.: calcd for C29H29ClF6OP2RuS2, C 45.23%, H 3.80%, S 8.33%; 851 
found, C 44.35%, H 4.05%, S 7.79%. 852 
Ru9′, [RuCl(η6-p-cymene)(κ2P,S-L9)]PF6. The procedure was the same as that followed to prepare 853 
Ru2′. Starting from Ru9 (30 mg, 0.039 mmol) and TlPF6 (14 mg, 0.040 mmol), the desired complex 854 
was obtained as a red solid. Yield: 30 mg (88%). 855 
1H NMR (400 MHz): 8.33–8.21 (m, M + m), 8.10–7.85 (m, M + m), 7.73–7.60 (m, M + m), 7.57–7.42 856 
(m, M + m), 7.42–7.27 (m, M + m), 7.18 (t, J = 7.7, 1H, M), 6.71 (d, J = 6.4, 1H, M), 6.44 (d, J = 6.4, 857 
1H, m), 6.38 (d, J = 5.6, 1H, m), 6.36 (d, J = 5.6, 1H, M), 5.87 (d, J = 6.4, 1H, m), 5.83(d, J = 6.8, 1H, 858 
M), 5.66 (d, J = 6.4, 1H, m), 5.10 (d, J = 6.0, 1H, M), 2.44 (sept, 3JHH = 6.8, 1H, M), 2.34 (sept, 3JHH 859 
= 6.0, 1H, m), 2.06 (s, 3H, M), 1.99 (s, 3H, m), 1.28 (d, 3JHH = 6.8, 3H, m), 1.07 (d, 3JHH = 7.2, 3H, 860 
M), 0.85 (d, 3JHH = 6.8, 3H, m), 0.44 (d, 3JHH = 6.8, 3H, M). 13C{1H} NMR (101 MHz, major 861 
isomer): 155.6–121.5 (C, CH, Ar), 112.0 (s, C), 105.3 (s, C), 96.9 (d, 2JCP = 7.6, CH), 89.0 (d, 2JCP = 862 
5.2, CH), 86.9 (s, CH), 86.6 (s, CH), 31.3 (s, CH), 23.2 (s, CH3), 18.8 (s, br, CH3), 18.3 (s, CH3). 863 
31P{1H} NMR (162 MHz): +50.1 (s, m), +44.4 (s, M). HRMS: calcd for C40H33ClOPRuS ([M] − 864 
PF6), 729.0716; found, 729.0742. 865 
Ru10′, [RuCl(η6-p-cymene)(κ2P,S-L10)]BF4. The procedure was the same as that followed to prepare 866 
Ru2′. Starting from Ru10 (60 mg, 0.098 mmol) and TlBF4 (29 mg, 0.10 mmol), the desired complex 867 
was obtained as a pale red solid. Yield: 50 mg (71%). 868 
IR: 3063, 2961, 2862, 1437, 1392, 1103, 1084, 1046 ν(BF4−), 898, 759, 696, 522. 1H NMR (400 MHz): 869 
8.18 (d, J = 7.2, 1H), 8.09–8.00 (m, 2H), 7.85–7.77 (m, 2H), 7.69–7.53 (m, 7H), 6.45 (d, J = 6.0, 1H, 870 
M), 6.41 (d, J = 6.4, 1H, m), 6.35 (d, J = 6.4, 1H, M), 6.27 (d, J = 6.4, 1H, m), 6.04 (d, J = 6.0, 1H, m), 871 
6.00 (d, J = 6.4, 1H, m), 5.74 (d, J = 6.4, 1H, M), 5.64 (d, J = 6.8, 1H, M), 2.70 (d, 2JHP = 10.4, 3H, m), 872 
2.51 (sept, 3JHH = 6.8, 1H, m), 2.45 (d, 2JHP = 11.6, 3H, M), 2.30 (sept, 3JHH = 7.2, 1H, M), 1.97 (s, 873 
3H, m), 1.88 (s, 3H, M), 1.18 (d, 3JHH = 6.8, 3H, M), 1.16 (d, 3JHH = 6.4, 3H, m), 0.95 (d, 3JHH = 6.8, 874 
3H, M), 0.90 (d, 3JHH = 6.8, 3H, m). 13C{1H} NMR (101 MHz, only the major isomer peaks are 875 
listed): 152.0–124.0 (C, CH, Ar), 112.9 (s, C), 104.3 (s, C), 94.5 (d, 2JCP = 5.8, CH), 89.8 (d, 2JCP = 876 
4.5, CH), 88.0 (d, 2JCP = 2.0, CH), 86.2 (d, 2JCP = 3.4, CH), 31.1 (s, CH), 22.0 (s, CH3), 21.4 (s, 877 
CH3), 17.9 (s, CH3), 12.2 (d, 1JCP = 36.9, CH3). 31P{1H} NMR (162 MHz): +47.4 (s, M), +39.8 (s, 878 
m). HRMS: calcd for C29H29ClPRuS ([M] − BF4), 577.0454; found, 577.0449. 879 
Ru11′, [RuCl(η6-p-cymene)(κ2P,S-L11)]PF6. The procedure was the same as that followed to prepare 880 
Ru2′. Starting from Ru11 (50 mg, 0.078 mmol) and TlPF6 (31 mg, 0.090 mmol), the desired complex 881 
was obtained as a dark red solid. Yield: 49 mg (84%). 882 
IR: 3062, 2965, 1470, 1436, 1390, 842 ν(PF6−), 760, 695, 558, 505. 1H NMR (400 MHz): 8.07 (t, J = 883 
8.0, 2H), 8.00 (d, J = 7.6, 1H), 7.71–7.59 (m, 5H), 7.51–7.43 (m, 4H), 6.58 (d, J = 6.8, 1H), 6.08 (d, J = 884 
6.0, 1H), 6.03 (d, J = 6.0, 1H), 5.87 (d, J = 6.4, 1H), 3.75 (m, br, 1H), 2.36 (sept, 3JHH = 6.8, 1H), 2.07 885 
(s, 3H), 1.43 (dd, 3JHH + 3JHP = 14.4, 6.4, 3H), 1.35 (dd, 3JHH + 3JHP = 20.4, 7.2, 3H), 1.11 (d, 3JHH 886 
= 7.2, 3H), 0.56 (d, 3JHH = 6.8, 3H). 13C {1H} NMR (101 MHz): 153.0–123.2 (C, CH, Ar), 113.3 (s, 887 
C), 97.9 (s, br, C), 93.7 (d, 2JCP = 6.3, CH), 91.6 (d, 2JCP = 5.7, CH), 91.3 (s, CH), 85.7 (s, CH), 31.4 888 
(s, CH), 29.3 (d, 1JCP = 27.0, CH), 23.1 (s, CH3), 19.4 (s, CH3), 18.4 (s, CH3), 18.2 (d, 2JCP = 4.5, 889 
CH3), 17.8 (d, 2JCP = 7.2, CH3). 31P{1H} NMR (162 MHz): +68.1 (s). Anal.: calcd for 890 
C31H33ClF6P2RuS, C 49.64%, H 4.43%, S 4.27%; found, C 49.68%, H 4.89%, S 4.09%. 891 
Ru12′, [RuCl(η6-p-cymene)(κ2P,S-L12)]PF6. The procedure was the same as that followed to prepare 892 
Ru2′. Starting from Ru12 (50 mg, 0.064 mmol) and TlPF6 (24 mg, 0.069 mmol), the desired complex 893 
was obtained as a red solid. Yield: 35 mg (61%). 894 
1H NMR (400 MHz): 8.20–8.00 (m, 4H), 7.76–7.47 (m, 8H), 6.27–6.22 (m, 3H, 1M + 2 m), 6.07 (d, J = 895 
6.4, 1H, M), 5.74 (d, J = 6.0, 1H, m), 5.63 (d, J = 7.2, 1H, m), 5.53 (d, J = 5.2, 2H, M), 5.18 (s, 1H, M), 896 
4.94 (s, 1H, M), 4.71 (s, 1H, m), 4.66 (s, 2H, M + m), 4.58 (s, 1H, M), 4.36 (s, 1H, m), 4.17 (s, 5H, M), 897 
4.01 (s, 5H, m), 3.99 (s, 1H, m), 2.43 (sept, 3JHH = 7.6, 1H, M), 2.30 (sept, 3JHH = 8.4, 1H, m), 1.77 898 
(s, 3H, m), 1.71 (s, 3H, M), 1.17 (d, 3JHH = 7.2, 3H, m), 0.97 (d, 3JHH = 6.8, 3H, M), 0.93 (d, 3JHH = 899 
7.2, 3H, M), 0.88 (d, 3JHH = 6.4, 3H, m). 13C{1H} NMR (101 MHz): 151.7–123.9 (C, CH, Ar), 113.1 900 
(s, C, m), 111.8 (s, C, M), 104.4 (s, C, m), 100.2 (s, C, M), 95.3 (d, 2JCP = 3.1, CH, M), 94.9 (d, 2JCP = 901 
5.6, CH, m), 90.5 (d, 2JCP = 3.8, CH, M), 90.1 (d, 2JCP = 3.4, CH, M), 89.2 (d, 2JCP = 3.9, CH, m), 902 
88.4 (s, CH, m), 86.8 (d, 2JCP = 3.8, CH, M), 86.7 (d, 2JCP = 3.5, CH, m), 76.5 (d, JCP = 10.4, CH, m), 903 
74.6 (d, JCP = 8.1, CH, M), 73.0 (d, JCP = 8.5, CH, m), 72.6 (d, JCP = 10.6, CH, m), 72.2 (d, JCP = 904 
14.4, CH, M), 71.5 (d, JCP = 9.4, CH, M), 71.3 (d, JCP = 11.8, CH, m), 70.9 (s, 5CH, m), 70.8 (d, JCP = 905 
6.2, CH, M), 70.3 (s, 5CH, M), 31.6 (s, CH, M), 31.2 (s, CH, M), 22.4 (s, CH3, m), 21.7 (s, CH3, M), 906 
21.2 (s, CH3, M), 20.9 (s, CH3, m), 18.1 (s, CH3, M), 17.6 (s, CH3, m). 31P{1H} NMR (162 MHz): 907 
+53.0 (s, m), +48.8 (s, M). HRMS: calcd for C38H35ClFePRuS ([M] − PF6), 747.0279; found, 908 
747.0293. 909 
Ru13′, [RuCl(η6-p-cymene)(κ2P,S-L13)]PF6. The procedure was the same as that followed to prepare 910 
Ru2′. Starting from Ru13 (136 mg, 0.21 mmol) and TlPF6 (81 mg, 0.23 mmol), the desired complex 911 
was obtained as a pale red solid. Yield: 100 mg (63%). 912 
IR: 3057, 2964, 2925, 1437, 1391, 1147, 1103, 841 ν(PF6−), 749, 694, 558. 1H NMR (400 MHz): 7.90 913 
(dt, J = 8.0, 1.6, 2H), 7.80–7.65 (m, 6H), 7.65–7.42 (m, 14H), 7.36 (dd, J = 12.0, 7.6, 2H), 6.62 (d, J = 914 
6.0, 1H, M), 6.57 (d, J = 6.4, 1H, M), 6.44 (d, J = 6.4, 1H, m), 6.39 (d, J = 6.4, 1H, m), 6.13 (d, J = 6.4, 915 
1H, M), 6.08 (d, J = 6.0, 1H, M), 5.53 (d, J = 6.4, 1H, m), 5.35 (d, J = 6.0, 1H, m), 2.53 (m, 1H, M), 2.41 916 
(m, 1H, m), 2.50 (d, 2JHP = 18.4, 3H, m), 2.46 (d, 2JHP = 10.0, 3H, M), 2.01 (s, 3H, m), 1.95 (s, 3H, 917 
M), 1.19 (d, 3JHH = 6.8, 3H, m), 1.15 (d, 3JHH = 6.8, 3H, M), 1.00 (d, 3JHH = 6.8, 3H, m), 0.88 (d, 918 
3JHH = 6.8, 3H, M). 13C{1H} NMR (101 MHz): 146.2–127.7 (C, CH, Ar), 113.5 (s, C, m), 113.1 (s, C, 919 
M), 104.0 (s, C, m), 101.4 (s, C, M), 97.4 (d, 2JCP = 5.8, CH, m), 94.8 (s, br, CH, M), 93.8 (d, 2JCP = 920 
4.5, CH, M), 92.5 (s, br, CH, M), 91.9 (d, 2JCP = 3.8, 2CH, 2 m), 89.9 (d, 2JCP = 3.8, CH, M), 89.3 (d, 921 
2JCP = 4.2, CH, m), 31.2 (s, CH, M), 30.9 (s, CH, m), 21.9 (s, CH3, M), 21.8 (s, CH3, m), 21.6 (s, CH3, 922 
m), 21.5 (d, 1JCP = 34.6, CH3, M), 21.0 (s, CH3, M), 18.1 (s, CH3, M), 18.0 (s, CH3, m), 11.8 (d, 1JCP 923 
= 40.2, CH3, m). 31P{1H} NMR (162 MHz): +54.9 (s, m), +50.0 (s, M). Anal.: calcd for 924 
C27H23ClF6O2P2RuS2, C 42.89%, H 3.07%, S 8.48%; found, C 42.95%, H 2.85%, S 7.75%. 925 
Ru11*′, [RuCl(η6-methyl benzoate)(κ2P,S-L11)]PF6. The procedure was the same as that followed to 926 
prepare Ru2′. Starting from Ru11* (130 mg, 0.20 mmol) and TlPF6 (78 mg, 0.22 mmol), the desired 927 
complex was obtained as a brown solid. Yield: 120 mg (73%). 928 
IR: 3092, 2959, 2872, 1734 ν(CvO), 1436, 1390, 1298, 1280, 1114, 840 ν(PF6−), 761, 695, 558. 1H 929 
NMR (400 MHz): 8.19 (d, J = 6.8, 1H), 8.04 (d, J = 8.0, 2H), 7.69–7.56 (m, 5H), 7.55–7.44 (m, 4H), 930 
7.21 (d, br, J = 5.2, 1H), 6.75 (d, J = 6.0, 1H), 6.49 (s, br, 2H), 5.84 (t, br, J = 5.2, 1H), 3.75 (m, 1H), 931 
3.73 (s, 3H), 1.43–1.33 (m, 6H). 13C{1H} NMR (101 MHz): 163.3 (CvO), 152.8–122.3 (C, CH, Ar), 932 
96.6 (d, 2JCP = 1.8, CH), 94.6 (d, 2JCP = 3.8, CH), 90.5 (s, CH), 89.3 (d, 2JCP = 5.4, C), 88.7 (d, 2JCP 933 
= 1.0, CH), 87.9 (d, 2JCP = 2.6, CH), 53.7 (s, CH3), 30.2 (d, 1JCP = 27.2, CH), 18.3 (d, 2JCP = 4.4, 934 
CH3), 17.8 (d, 2JCP = 7.1, CH3). 31P{1H} NMR (162 MHz): +67.8 (s). HRMS: calcd for 935 
C29H27ClO2PRuS ([M] − PF6), 607.0201; found, 607.0205. 936 
 937 
Ru-catalysed transfer hydrogenation 938 
A 100 ml Schlenk flask was charged with the ruthenium precursor (0.02 mmol) and potassium tert-939 
butoxide (11.2 mg, 0.1 mmol) and purged with three vacuum/nitrogen cycles. Under a gentle flow of 940 
nitrogen, 25 ml of 2-propanol were added and the flask heated to reflux (85 °C) for 15 minutes. After 941 
that time, acetophenone (0.47 mL, 4.0 mmol) was rapidly added to start the catalytic run. The reaction 942 
was monitored at the allotted times by taking aliquots of around 0.1 mL and analysing them by GC. 943 
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Fig. 1 ORTEP representation (thermal ellipsoids are drawn at the 50% probability level, H atoms are 1098 
removed for clarity) of 4-DBF-Fc (left) and 4-DBT-Fc (right). Distances (Å) and angles (°) for 4-DBF-1099 
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91.6(2). 1105 
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Scheme 5 Unsuccessful synthesis of 4-DBTO2-Me. 1107 
 1108 
Scheme 6 Preparation of 3-DBTO2. 1109 
 1110 
Scheme 7 Free phosphinites and phosphines L1–13. 1111 
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Scheme 8 Preparation of neutral ruthenium complexes. 1113 
 1114 
Scheme 9 Two possible isomers of the Ru complexes observed by 13C{1H} NMR spectroscopy. 1115 
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Fig. 2 ORTEP representations (thermal ellipsoids are drawn at the 50% probability level, H atoms are 1117 
removed for clarity) of Ru5, Ru6 and Ru10 (from left to right). The most relevant distances and angles 1118 
are given in Table 1. 1119 
 1120 
Scheme 10 Preparation of cationic ruthenium complexes. 1121 
 1122 
Scheme 11 Ru-catalysed enantioselective transfer hydrogenation of acetophenone. 1123 
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